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Abbreviations 
°C   degrees Celsius 
µ   micro 
3’   three prime end of DNA sequences 
5’   five prime end of DNA sequences 
A   adenosine 
AceCS2 acetyl coenzyme A synthetase 2 
ADP  adenosine diphosphate 
ADPR  ADP ribose 
AKT   proteinkinase B 
as  antisense 
ATP  adenosine triphosphate 
C   cytosine 
Caggs  chicken β-actin-promoter with CMV enhancer 
cDNA   complementary DNA 
CMV  cytomegalovirus   
CNS   central nervous system 
CPS1  carbomyl phosphate synthetase 1 
CR  caloric restriction 
Cre   site specific recombinase from phage P1 (causes recombination) 
Ct  cycle treshold 
Da   Dalton 
ddH2O  double destilled water 
DMSO  dimethylsulfoxide 
DNA   desoxyribonucleic acid 
DNase   desoxyribonuclease 
dNTP   desoxyribonucleotide-triphosphate 
Dox  doxycycline 
DSE  distal sequence element 
dsRNA double stranded RNA 
DTT   Dithiothreitol 
E.coli  Escherichia coli 
e.g.   exempli gratia 
ECL   enhanced chemiluminescence 
EDTA  ethylendiamine tetraacetate 
ELISA  enzyme-linked immunosorbent assay 
EtBr   ethidium bromide 
EtOH   ethanol 
EWAT  epigonadal white adipose tissue 
floxed   loxP flanked 
Flp  flippase 
Fluc  firefly luciferase 
FOXO1  forkhead-O transcription factor 1 
FRT  flip-recombinase targets 
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g   gram 
G   guanine 
G418  geneticin 
GAPDH glycerinaldehyd-3-phosphate dehydrogenase 
GDH  glutamate dehydrogenase 
GTT   glucose tolerance test 
h   hour 
H&E   hematoxylin/eosin 
HCl   hydrochloric acid 
HDAC  histone deacetylase 
HEPES  N-2-hydroxyethylpiperazine-N’-2-ethansulfonic acid 
HFD   high-fat diet 
Hp1bp3 heterochromatin protein1 binding protein3 
Hygro  hygromycin 
Hz  Hertz 
i.p.   intraperitoneal 
IR   insulin receptor 
itetR  codon optimized version of tetR 
ITT   insulin tolerance test 
k   kilo 
kb   kilobase pairs 
KCl   potassium chloride 
kDa   kilodalton 
l   liter 
lacZ   gene encoding the enzyme beta-galactosidase 
loxP   recognition sequence for Cre (locus of x-ing over phage P1) 
m   milli 
M   molar 
mES cells mouse embryonic stem cells 
MgCl2   magnesium chloride 
min   minute 
miRNA micro RNA 
mRNA  messenger RNA 
NaCl   sodium chloride 
NAD  nicotinamide adenine dinucleotide 
NADH  nicotinamide adenine dinucleotide reduced 
NAM  nicotinamide 
NaOH   sodium hydroxide 
NCD   normal chow diet 
Neo  neomycin 
NMR   nuclear magnetic resonance 
Nt  nucleotide 
OD   optical density 
ORF  open reading frame 
PAGE   polyacrylamid gel electrophoresis 
pAhGH human growth hormone poly adenylation 
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PB   phosphate buffer 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PGC-1α PPARγ coactivator-1 
PGK  phosphoglycerate kinase 
PIE  promoter inhibitory element 
Pol III  RNA polymerase III 
PPARγ peroxisome proliferator-activated receptor gamma 
PSE   proximal sequence element 
Puro  puromycin 
qRT-PCR quantitative realtime PCR 
rDNA  ribosomal DNA 
RISC  recombinase mediated cassette exchange 
Rluc  renilla luciferase 
RMCE  recombinase mediated cassette exchange 
RNA   ribonucleic acid 
RNAi   RNA interference 
RNAi  RNA interference 
RNAi  RNA interference 
RNase  ribonuclease 
RT   room temperature 
rtTA  reverse tetracycline transactivator 
s  sense 
SDS   sodiumdodecylsulfate 
sec   second 
SEM   standard error of the mean 
SGK1   serum- and glucocorticoid regulated kinase 1 
shRNA short hairpin RNA 
siRNA  short interfering RNA 
SNP  single nucleotide polymorphism 
T3   triiodothyronine 
TAE   Tris-acetic acid-EDTA buffer 
TBS   Tris buffered saline 
tetO  tetracycline operator 
tetR  tetracycline repressor 
Tris   2-amino-2-(hydroxymethyl-)1,3-propandiole 
tTA  tetracycline transactivator 
U   units 
UTR  un-translated region 
V   Volt 
v/v   volume per volume 
VO2   volume of oxygen 
VP  viral protein 
w/v   weight per volume 
Zsgreen Zoanthus sp. green fluorescent protein 
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1 Introduction 
 
1.1 RNA interference  
RNA interference (RNAi) is a cellular mechanism to regulate gene expression by 
sequence-specific posttranscriptional gene silencing. First described in 1998 by Fire and Mello 
in the invertebrate nematode Caenorhabditis elegans (1), RNAi became more attention and it 
has since been studied in a wide range of eukaryotic organisms such as fungi, flies, plants and 
mammals (2). Originally, RNAi had probably evolved to an important defence mechanism in 
many organisms against viruses, inverted repeat transgenes, or transposable elements that 
include a double strand RNA (dsRNA) step in their replication cycle (3). When present within 
a cell, dsRNAs are recognized by the ribonuclease called Dicer and are further converted into 
smaller dsRNA molecules of 21 base pairs with a 2-nucleotide 3´-overhangs (4). These 
molecules are called short interfering RNAs (siRNAs) that direct RNAi (5-8). SiRNAs are then 
shuttled into an RNAi-specific protein complex to form the RNA-induced silencing complex 
(RISC) (Figure 1). This ribonucleoprotein complex might undergo activation in the presence of 
ATP so that the antisense component of the unwound siRNA becomes exposed and paired with 
the cognate mRNA (9, 10). Subsequently, the RISC complex recognize and cleaves 
homologous mRNA endonucleolytically, thereby decreasing the production of the 
corresponding protein (11, 12). Thus, any mRNA bearing a homologous sequence with an 
appropriate siRNA is degraded and its expression is knocked down to 10-40 % of its normal 
levels (13). The assembly of RISC is asymmetrical with a clear strand bias (14), meaning that 
only one strand of the duplex is preferentially loaded (15) while the other strand will be 
destroyed. The strand whose 5´end has lower internal stability is preferentially incorporated 
into RISC. Thus, antisense (guide) strand of chemically synthesized siRNAs should have lower 
internal stability of its 5´end and is an important parameter for siRNA design. This is further 
supported by Reynolds and colleagues, who found few sequence specific characteristics (16). 
Most of the rules for siRNA design were implemented in various software programs, whereas 
many of them incorporate the original Tuschl algorithm. Studies have revealed that siRNA 
specificity is not as stringent since pairing between the hexamer seed region of a siRNA guide 
strand (nucleotides 2-7) and complementary sequences in the 3´UTR of mature transcripts has 
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been implicated in off-target gene regulation and false positive phenotypes (17-19). In a 
minority of siRNA based experiments, unspecific effects due to immune stimulation or 
saturation of the RNAi machinery have been described (20, 21). Appropriate control 
experiments, such as transfection of different siRNAs directed against the target mRNA may 
anticipate off-target effects. 
As longer dsRNAs provoke an interferon response in mammalian cells, leading to non-
specific mRNA degradation and global inhibition of protein translation rather than the desired 
specific knockdown, the technology was initially restricted to organisms showing no interferon 
response, such as Caenorhabditis elegans and Drosophila melanogaster  (5, 22). However, 
dsRNAs shorter than 30 bp were shown to circumvent interferon response in mammalian cells 
(5). Since efficient knockdown in transfected mammalian cells were first described with in 
vitro synthesized siRNAs (5, 6), RNAi techniques have become widely used an experimental 
tool to define the functional roles of individual genes, particularly in disease. 
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Figure 1: The small-interfering RNA (siRNA) pathway 
DsRNAs or vector based shRNAs are processed into siRNAs by the ribonuclease called Dicer (4). SiRNAs are 
incorporated in the RNA-induced silencing complex (RISC) and ATP-dependent unwinding of siRNAs activates 
RISC (10). Active RISC is thus guided to degrade the specific target mRNAs (11, 12). 
(abbreviations: dsRNA=double stranded RNA; shRNA=short hairpin RNA; siRNA=short interfering RNA; 
RISC=RNA induced silencing complex; mRNA=messenger RNA) 
 
1.2 shRNA/siRNA based RNAi in mammalian cells 
In mammalian cells, RNAi can be induced artificially by introducing chemically 
synthesized siRNAs (5). The design of effective siRNAs can be supported by several 
algorithms available (16, 23-25). Although siRNAs are easy to produce and their effects are 
transient in actively replicating cells, the duration of silencing is dependent of rate on cell 
division that can be 3-7 days in proliferating cells, but can persist for 3 weeks and more in 
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terminally differentiated cells, such as neurons (26). Subsequently, several large-scale RNAi 
screens have been conducted in mammalian tissue culture cells using synthetic siRNAs (27). 
These screens have identified genes involved in apoptosis, signalling, regulation of protein 
stability and the ultraviolet radiation damage response. On the other hand, RNAi based 
screening in mammalian cells have been limited to easily transfectable, rapidly dividing 
adherent cell types (28).  
An alternative provides the expression of short hairpin RNAs (shRNAs) (29-31) 
resulting in intracellular production of siRNA molecules by recruiting the endogenous 
processing machinery (32, 33). While transient transfection is advantageous for fast analysis of 
shRNA mediated effects, stable transfection ensures long-term, reproducible as well as defined 
shRNA effects. ShRNA expression vectors have been engineered using both viral (including 
retroviral (34), adenoviral (35, 36) and lentiviral (37) vectors), and plasmid systems (32, 38, 
39). Plasmids containing RNA polymerase III (pol III) dependent promoters, like those of the 
U6 and H1 genes are perfectly suited to produce double-stranded short hairpin RNAs 
(shRNAs) that are processed into siRNAs inside the cell (28) (Figure 1). The localization of the 
regulatory sequences immediately upstream of the Pol III transcription start site ensures 
expression of exact shRNA sequences without additional or unwanted nucleotides, a critical 
requirement for precise siRNA function (40). Promoters of this type are preferred as they 
naturally direct the synthesis small RNA transcripts with defined termination sequences 
consisting of 4–5 thymidines (the termination signal for RNA polymerase III) and have no 
requirement for downstream promoter elements (41-43). Further, pol III dependent promoters 
are constitutively expressed in all cell types and display a high level of activity (43). To 
increase their utility for cell culture studies, vectors that mediate inducible pol III dependent 
expression of siRNAs were developed (44-46).  
 
1.3 RNAi in transgenic animals 
Transgenic RNAi finds tremendous applicability in the creation of in vivo animal 
models mimicking gene knockout animals (47). The major advantage of shRNA transgenes is 
that they do not have to be bred into homozygosity to see the knockout effect as they behave 
like dominant-negative alleles (40). In addition, transgenic RNAi is less time consuming in 
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generation. The effect of RNAi in different cell types of mice have been demonstrated through 
injection of shRNA expression vectors into the tail vain (48, 49).  Moreover, gene knockdown 
in multiple tissues of mice or rats can be achieved by random transgenesis including random 
ES cell transfection, pronucleus injection or lentiviral transduction (50-55). Since random 
transgenesis in these experiments demonstrated various shRNA expression patterns in each 
individual mouse line, predicted RNAi from a defined genomic locus has been shown 
efficiently and applicable (56). 
However, vector mediated RNAi has limited germline transmission to only those 
shRNAs targeting genes whose knockdown is compatible with viability and fertility. Therefore, 
conditional RNAi approaches are an appropriate tool for the elucidation of gene function at 
varied levels of gene expression and generation of mice with mild phenotypes when gene 
knock-out is fatal. Today, shRNA expression can be either activated by temporal control (e.g. 
the tet-inducible systems) or in a tissue specific manner (e.g. the Cre/loxP system).  
 
1.3.1 Tissue specific RNAi in transgenes using the Cre/loxP system  
A number of important biological questions can be addressed simply by a knockdown 
of a gene of interest at a given tissue in the adult mouse. The Cre/loxP recombination system 
allows for this type of control and implicates a Cre recombinase derived from bacteriophage P1 
and two 34 bp loxP (locus of crossover (x) in P1) sites (include two 13 bp palindrome 
sequences separated by a spacer fragment of 8 bp), recognized by Cre (57). Cre-mediated 
catalysis results in a reciprocal recombination between the two similarly oriented loxP sites, 
followed by an excision of the DNA segment between the loxP sites leaving a single loxP site 
behind. In contrast, recombination between inverted loxP sites causes inversion of the 
sequence placed between them. The U6 promoter is preferably used for the Cre/loxP based 
RNAi systems and consists of three tightly spaced elements. Distal and proximal sequence 
elements (DSE and PSE) are 5´ of the TATA box that is located 26 bases downstream from 
transcriptions initiation. Several groups have developed strategies to activate RNAi upon Cre-
excision (58-64). Tissue specific control of shRNA expression can be achieved by insertion of 
a loxP flanked stop cassette close to the TATA box of the pol III dependent promoter, thereby 
blocking transcription. Excision of the stop cassette through Cre mediated recombination 
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results in gene silencing in a given tissue (61, 63, 65).  In another approach, the loxP flanked 
stop cassette was placed between the DSE and PSE regulatory elements of the U6 promoter. 
Since a single loxP site in the same position does not interfere with transcription, the system 
allows controllable RNAi through Cre mediated recombination of the stop cassette. A further 
strategy employed a loxP flanked stop cassette that is embedded in the loop of the shRNA (60-
62). Upon Cre recombination, the single loxP site is part of shRNA transcript. A loss of RNAi 
potency has not been observed (61). 
The Cre/loxP system has also been applied for temporal control of shRNA expression. 
Cre recombinase activity was regulated by using a tamoxifen controllable Cre-ER fusion 
protein (66-68). However, Cre mediated excision of a DNA fragment is a one-time and 
irreversible event thereby reducing its usefulness for many applications.  
 
1.3.2 Inducible RNAi in transgenes using the tet-system 
A well-defined regulatory system of Escherichia coli (E.coli) is the tet operon that can 
be used to direct temporal control of shRNA expression and inducible gene silencing (45, 69). 
The tet inducible based system uses the transposon 10 (Tn10) specified tetracycline-resistance 
(tet) operon of E. coli (70). Activity of the tet operon is regulated by the tet repressor (tetR) 
which binds to a DNA sequence termed an operator (tetO) in the absence of tetracycline, 
resulting in transcriptional repression. Tet inducible RNAi vectors have been created by 
inserting a tetO sequence in the pol III promoter between the TATA box and the transcription 
start without altering the position of the promoter elements relative to each other or with 
respect to the transcription start site (45, 69, 71). In the absence of the inducer doxycycline, the 
tetR binds on the tetO thereby sterically hinders binding of polymerase III to the modified H1 
promoter whereas shRNA expression is “off”. Upon addition of dox which binds to the tetR, 
the tetR undergoes a conformational change that results in reduced binding to the tetO with a 
subsequent activation in shRNA production (72). Several approaches have been performed to 
apply this strategy for the temporary control of antisense or shRNA expression in cultured cell 
lines (44, 45, 71, 73) as well as in mice and rat (69, 74, 75). One main drawback of this system 
is the leaky expression in vivo in the un-induced state, which can be diminished by using of a 
codon optimized version of the tetR (itetR) (45, 69, 76).  
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First approaches implying the tet inducible shRNA expression system were performed 
on mouse xenograft tumormodels. Immunocompromised mice harboring the tet inducible 
RNAi system and implanted tumor cells, developed tumor growth as normal in the absence of 
dox and repressed promoter. As demonstrated on several studies, dox treatment initiated 
silencing of pro-cancerous genes that yielded in tumor regression. Thus, tet inducible RNAi 
served as a valuable tool for loss-of-function screens of genes, required for the proliferation 
and survival of cancer cells (77). 
 
1.4 Tissue specific and inducible RNAi in mice 
The temporal and spatial control of gene inactivation avoids embryonic lethality and 
permits to dissect gene function at high precision. However, these unique approaches do not 
fully exploit the major experimental advantage of RNAi: in principle, its effects can be 
simultaneously: tissue specific and inducible. In the following three concepts, different 
principles have been demonstrated for a transgenic RNAi technology that can be used for 
spatially, temporally and reversible regulated gene expression of any target gene. Yu and 
McMahon developed a strategy for Cre-mediated activation of shRNA transcription in mouse 
ES cells (68). In addition, these cells contained a Cre-ER fusion transgene whose recombinase 
activity was controlled by the inductor 4OH-tamoxifen. The system has been shown to be 
applicable in vitro as well as in chimeric embryos (68). In the approach of Dickens and his 
colleagues (78), transgenic mice with a tet-regulatable shRNA expression cassette were 
generated and crossed with a transgenic tet transactivator mouse line. These double-transgenic 
mice produced shRNAs in a tissue specific manner that can be regulated by doxycycline (78). 
A new strategy developed and focused within this work relied on the use of site-specific 
recombination by the Cre/loxP technology according to inducible shRNA transcription by the 
tetO/tetR system.  
 
1.5 The mammalian sirtuins 
The founding member of the sirtuin family of histone deacetylases (HDACs) was the 
silent information regulator 2 (Sir2) of the budding yeast Saccharomyces cerevisiae (79). In 
  Introduction 
 19 
yeast, Sir2 has been shown to mediate the effects of calorie restriction on the extension of life 
span, thus longevity is promoted by high levels of Sir2 activity (80, 81). In mammals, seven 
sirtuins (Sirt1-7) have been identified, each of them sharing a conserved 275-amino-acid 
catalytic core domain. Like their yeast homologs, the mammalian sirtuins (Sirt1-7) are class III 
HDACs and require nicotinamide adenine dinucleotide (NAD+) as a cofactor (82) to 
deacetylate substrates ranging from histones to transcriptional regulators (83). The 
deacetylating enzymatic activity of sirtuins uses NAD+ as a catalyst to transfer the acetyl group 
from proteins and peptides to the ADP-ribose (ADPR) moiety of NAD+, yielding the acetyl 
ester metabolites 2’-O- and 3´-O-acetyl-ADP-ribose (AADPR), nicotinamide (NAM) and the 
deacetylated protein (Figure 2). The nicotinamide ribosyl bond is cleaved and one net water 
molecule is added to nicotinamide ribose, a reaction unique to sirtuins (84). The deacetylation 
activity of the sirtuins is controlled by the cellular [NAD+]/[NADH] ratio and thus differs from 
other HDACs. NAD+ thereby activates whereas nicotinamide and reduced nicotinamide 
adenine dinucleotide (NADH) inhibits the deacetylation process (85-89). Thus, depending on 
cellular [NAD+]/[NADH] ratios and NAM levels, sirtuins may facilitate the conversion of 
nutritional status into modulation of gene and protein function, leading ultimatively to changes 
in cellular function (90). Two Sirtuins, Sirt4 and Sirt6 possess NAD+-dependent ADP-ribosyl 
transferase activity (Figure 2), the biological significance of which is less well understood (91-
93). In addition, Sirt2 and Sirt6 have been shown to perform both the ADP-ribosyl transferase 
and deacetylation activity (93, 94).    
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Figure 2: Deacetylation and ADP-ribosylation activity by mammalian sirtuins 
Sirtuins are NAD+-dependent deacetylases and mono-ADP-ribosyl transferases. Sirt1-3 and Sirt5 catalyze a 
deacetylation reaction by transferring the acetyl lysine residues of the target protein to the ADP-ribose (ADPR) 
moiety of NAD+ which generates the byproducts 2’-O- and 3´-O-acetyl-ADP-ribose (AADPR), nicotinamide 
(NAM) and the deacetylated protein (95-97). Sirt4 and Sirt6 possess ADP-ribosyl transferase activity (91, 92, 94). 
The Figure is taken from (98). 
 
 
Mammalian sirtuins are found in numerous compartments within the cell (Table 1). Sirt1, Sirt6 
and Sirt7 are found predominantly in the nucleus (82, 83, 99); Sirt3, Sirt4 and Sirt5 (79, 99, 
100) are located in mitochondria and Sirt2 resides predominantly in the cytoplasm (79, 101). 
However, Sirt1 and Sirt2 were found to shuttle between the nucleus and the cytoplasm and to 
interact with both nuclear and cytosolic proteins (102, 103). 
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Table 1: Main characteristics of mammalian sirtuins 
Abbreviations: AceCS2, acetyl-CoA-synthetase2; ANT, adenide nucleotide translocator; CPS1, carbamoyl 
phosphate synthetase 1; FOXO, forkhead box, subgroup O; GDH, glutamate dehydrogenase; IDE, insulin 
degrading enzyme; NF-ĸB, nuclear factor kappa B; PGC-1α, peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha; Pol I, DNA polymerase I; rDNA, recombinant DNA. The table is taken from (104). 
 
1.6 Regulatory functions of the sirtuins 
1.6.1 Sirt1 
The best characterized family member of the sirtuin family in terms of its endogenous 
function and activity is Sirt1. Sirt1 has been linked to the control of metabolic processes  in 
adipose tissue, liver and muscle through the regulation of the nuclear receptor peroxisome-
proliferator activated receptor-γ (PPAR γ) and its transcriptional co-activator PPARγ co-
activator-1α (PGC-1α) (105-108). A specific knockdown of Sirt1 in liver leads to decreased 
expression of gluconeogenic genes and glucose output (109, 110). These mice demonstrate 
mild hypoglycemia, increased systemic glucose as well as elevated insulin sensitivity due to 
the because of decreased glucose production. In pancreatic β-cells, Sirt1 is known to positively 
regulate glucose stimulated insulin secretion (111, 112), whereas it is able to modulate the 
expression (113) and secretion (114) of adiponectin, a hormone that enhances insulin sensivity 
from adipocytes. Further non-histone substrates are the tumor suppressor p53, the FOXO 
family of forkhead box transcription factors and NF-ĸB transcription factors, which are 
involved in the regulation of cell survival, proliferation and stress response (106, 115-117). 
Sirt1 has also been linked to the survival of neurons. The survival of cultured neuronal cells 
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can be promoted by Sirt1, probably through deacetylation-mediated downregulation of the pro-
apoptotic factors p53 (115, 118) and FOXO (116, 119). Overexpression of Sirt1 and the 
addition of the Sirt1 agonist resveratrol reduced NF-ĸB signalling in β-amyloid-induced death 
of microglia (120). Finally, Sirt1 null mice were shown to result in metabolically inefficient 
animals that failed to adapt to caloric restriction (CR) conditions, suggesting that Sirt1 is 
required for response to CR (121). 
 
1.6.2 Sirt2 
Compared to the Sirt1, the function of Sirt2 is less well understood. Mammalian Sirt2 
resides predominantly in the cytoplasm and is involved in cytoskeleton organization by 
targeting the cytoskeletal protein α-tubulin (101). Sirt2 has been implicated in cell cycle 
regulation (102, 122-125). Its expression correlates with cell cycle progression and peaks in 
mitosis. Functionally, Sirt2 is considered a mitotic exit regulator. Overexpression of Sirt2 
delayed mitotic exit in response of stress (123, 126, 127) whereas Sirt2 inhibition prolongs 
chronic mitotic arrest, preventing cell death during re-entry into the cell cycle (127). 
Contrastingly, under normal and non-stress inducing cell culture conditions, Sirt2 did not affect 
cell cycle progression (128). In addition, the Sirt2 catalytic mutant increased the number of 
multinucleated cells (102, 124), indicating that precise levels of Sirt2 are required for mitotic 
fidelity. Sirt2 has also been suggested to act as a tumor suppressor gene in human gliomas 
(129), since downregulation of Sirt2 gene expression or deletion of the chromosomal region 
harboring the Sirt2 gene is frequently observed in this type of tumor.  
Sirt2 protein expression is induced by caloric restriction most predominantly in white 
adipose tissue and kidney. Furthermore, in 3T3-L1 murine adipocytes, Sirt2 mRNA levels 
were elevated by oxidative stress (130). In cultured pre-adipocytes and in adipocytes in vivo, 
Sirt2 was demonstrated to be the most abundant sirtuin (131). Moreover, overexpression of 
Sirt2 inhibited adipogenesis, whereas reducing Sirt2 expression had the opposite effect. This 
effect was attributed to Sirt2 mediated regulation of FoxO1 deacetylation (131, 132). Sirt2 can 
be phosphorylated by various cyclin dependent kinase complexes (124, 128) and 
dephosphorylated by CDC14B phosphatase (126), which might down-regulate Sirt2 function. 
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Amongst all sirtuins, Sirt2 expression was found strongest in the brain (128, 133). 
Further, Sirt2 was described as an oligodendroglial cytoplasmic protein localized in the myelin 
sheath, decreasing cell differentiation through α-tubulin deacetylation (133-135). It was 
concluded that its function might be to prevent premature differentiation or early aging of these 
cells. NAD+-mediated deacetylation activity of Sirt2 influences axonal degeneration (136) and 
microtubule acetylation (133), thus influencing neuronal function. In neurons, Sirt2 is rather 
uniformly expressed in all neurits and their growth cones (128). Whereas Sirt1 has been mainly 
attributed neuroprotective effect e.g. in DNA damage (137) and in model systems of 
Alzheimer’s disease (120, 138-140), Sirt2 appears to promote neurodegeneration. For instance, 
Sirt2 inhibition resulted in rescue of alpha-synuclein toxicity in Parkinson’s disease models 
(141, 142). Conversely, Sirt2 enhances axon degeneration in a mouse model of Wallerian 
degeneration (136). 
 
1.6.3 Sirt3, 4 and 5 
Sirt3, 4 and 5 are localized within the mitochondrial matrix (91, 100, 143-147). Sirt3 
possess a mitochondrial signal peptide that is cleaved off  after import into mitochondria, 
necessary for full enzymatic activity (100). Expression of Sirt3 is strong in brown adipose 
tissue and induced by cold exposure (148). It also appears to regulate mitochondrial function, 
as its overexpression increases respiration, while at the same time decreasing reactive oxygen 
species (ROS) production (148). The mitochondrial protein acetylcoenzyme A synthase 2 
(AceCS2) was the first substrate identified for Sirt3 (149, 150). AceCS2 is a mitochondrial 
matrix enzyme that converts acetate to acetyl-CoA in the presence of ATP (151). Deacetylation 
of AceCS2 by SIRT3 activates its enzymatic activity (149, 150). Sirt3 also regulates ATP 
synthesis directly by changing the acetylation level of mitochondria electron transport 
Complex I (152). 
Unlike Sirt3, Sirt4 lacks detectable NAD+-dependent deacetylase activity in vitro, but 
demonstrates ADP-ribosyl transferase activity (91, 143, 153). Sirt4 is a ubiquitously expressed 
gene, with highest levels in the kidney, heart, brain, liver, and pancreatic beta cells (91, 143). 
Furthermore, Sirt4 has been reported to down regulate glutamate dehydrogenase (GDH) by 
ADP ribosylation and negatively regulate both, glucose and amino acid stimulated insulin 
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secretion(91) whereas Sirt4 knockout mice display higher GDH activity and levels of blood 
insulin (91).  
Recently it was demonstrated that Sirt5 regulates ammonia entry into the urea cycle 
(146). Sirt5 functions as a weak NAD+-dependent deacetylase and Sirt5 knockout mice 
developed normally without obvious metabolic defects (146). Sirt5 is known to interact and 
deacetylate carbomyl phosphate synthetase 1 (CPS1), which is the rate-limiting first step of the 
urea cycle. Its activity is required for clearing ammonia generated by amino acid metabolism. 
Mice lacking Sirt5 displayed elevated ammonia levels after a prolonged fast, suggesting that 
this sirtuin is necessary for dealing with byproducts of amino acid metabolism (146). 
 
1.6.4 Sirt6 and Sirt7 
Sirt6 and Sirt7 are found in the nucleus and in the nucleolus, respectively (83, 99). 
Beside its NAD+-dependent deacetylase activity and modulating telomeric chromatin (94), 
Sirt6 has also been shown to demonstrate a robust auto-ADP-ribosyl transferase activity, that 
plays a role in DNA repair and human aging (92, 154). Mice with a Sirt6 knockout displayed 
severe developmental defects, such as hypoglycemia, and suffered from premature aging (154). 
Additionally, in a recent study Sirt6 was found to regulate tumor necrosis factor (TNF) 
production (155). 
In the nucleolus, Sirt7 associates with rDNA and interacts with RNA polymerase I (Pol 
I) (156). It may regulate cell growth and metabolism in response to changing metabolic 
conditions by driving ribosome biogenesis in dividing cells (156). 
 
Taken together, mammalian sirtuins have diverse cellular locations, target multiple 
substrates including histones and non-histone substrates and affect a broad range of cellular 
functions. In some organisms, sirtuin have been shown to be regulated by and to mediate the 
effects of the dietary regimen CR. Moreover, current data indicate that these proteins are 
interesting therapeutic targets for metabolic and neurodegenerative diseases. Among all 
sirtuins, Sirt1 is the best characterized member to date, while the in vivo function of the other 
family members is incompletely understood. Moreover, in vitro experiments have provided 
results implicating Sirt2 in adipose tissue metabolism and neuronal survival, thus experiments 
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aiming to delineate the role of Sirt2 in energy homeostasis and neurodegenerative disease in 
vivo appear will be highly informative.  
 
1.7 Objectives 
The first part of this study aimed at the development of a system that allows temporally 
and spatially controlled gene silencing in mice to study directed gene function analysis in a 
selected tissue. To test, if this system is applicable for in vivo studies, the knockdown 
efficiency was determined, using a shRNA against the mouse endogenous target Sirt2 in mice.   
The second aim was to explore the role of Sirt2 in vivo. To this end, transgenic mice 
were generated with a ubiquitous Sirt2 knockdown using an existing inducible RNAi system. 
These mice were physiologically characterized under conditions of a normal diet and high fat 
diet in terms of metabolic pathways, including adipogenesis, glucose and insulin homeostasis, 
embryogenesis and a model of neurodegenerative disease.  
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2 Material and Methods 
2.1 Chemicals 
Size markers for agarose gel electrophoresis (1kb Plus DNA Ladder, O`GeneRuler, ready 
to use) and for SDS-PAGE (peqGOLD Prestained Protein-Marker IV) were obtained from MBI 
Fermentas, St. Leon-Rot, Germany and from Peqlab Biotechnologie, Erlangen, Germany, 
accordingly. Chemicals used in this work are listed below in table 2. 
 
Chemical   Supplier, origin 
α-[32P]-dCTP PerkinElmer Life Science, Köln, Germany 
β-mercaptoethanol Fisher Scientific, Schwerte, Germany 
10x PCR buffer  Invitrogen, Karlsruhe, Germany 
20x saline-sodium citrate (SSC) Invitrogen, Karsruhe, Germany 
4-2-hydroxyethyl-1-piperazineethanesulfonic 
acid  (HEPES) 
Sigma Aldrich, Steinheim, Germany 
Agarose ultra pure Invitrogen, Karlsruhe, Germany 
Albumine from bovine serum Sigma Aldrich, Steinheim, Germany 
Ampicilin 
 
VWR International, Langenfeld, Germany 
Bromophenol blue Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
Complete protease inhibitor cocktail tablets Roche Diagnostic, Mannheim, Germany 
Desoxyribonukleotide triphosphate set 
(dNTP)   
5 Prime, Hamburg, Germany 
Dithiothreitol (DDT) Sigma Aldrich, Steinheim, Germany 
Doxycycline hyclate Sigma Aldrich, Steinheim, Germany 
Ethanol absolute Merck, Darmstadt, Germany 
Ethidium bromide tablets VWR International, Langenfeld, Germany 
Ethylenediaminetetraacetic (EDTA) Sigma Aldrich, Steinheim, Germany 
G153 Developer Agfa Healthcare, Mortsel, Belgium 
G354 Fix Agfa Healthcare, Mortsel, Belgium 
Geneticin (G418) Sigma Aldrich, Steinheim, Germany 
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Glucose 20% Bela-pharm, Vechta, Germany 
Glycerol Merck, Darmstadt, Germany 
Guanidine hydrochloride AppliChem, Darmstadt, Germany 
Hydrochloric acid (HCl) Sigma Aldrich, Steinheim, Germany 
Insulin human Novo Nordisk, Basvaerd, Denmark 
Isopropanol TH. Geyer & Co, Renningen, Germany 
Lysogeny Broth (LB)  
 
Sigma Aldrich, Steinheim, Germany 
Magnesium chloride (MgCl)  Invitrogen, Karlsruhe, Germany 
PeqGOLD TriFast Peqlab, Erlangen, Germany 
Phenol-Chloroform-Isoamyl alcohol Applied Biosystems, Darmstadt, Germany  
Phosphatase inhibitor cocktail tablets, 
PhosSTOP 
Roche Diagnostic, Mannheim, Germany 
Phosphate buffered saline (PBS) Gibco Invitrogen, Karlsruhe, Germany 
Protein A Agarose Millipore, Eschborn, Germany 
Proteinase K 5 Prime, Hamburg, Germany 
QIAzol lysis reagent Qiagen, Hilden, Germany 
Reporter gene assay lysis buffer  Roche Diagnostic, Mannheim, Germany 
RNAlater Applied Biosystems, Darmstadt, Germany  
Salmon sperm DNA solution ultra pure, 
sonificated 
Fisher Scientific, Schwerte, Germany 
Sodium chloride 0,9% (NaCl) B. Braun, Melsungen, Germany 
Sodium dodecyl sulfate (SDS) Sigma Aldrich, Steinheim, Germany 
Sodium hydroxide (NaOH) VWR International, Langenfeld, Germany 
Sucrose Sigma Aldrich, Steinheim, Germany 
Super Signal West Pico chemiluminescent 
substrate 
Fisher Scientific, Schwerte, Germany 
Tris acetate EDTA (TAE) Fisher Scientific, Schwerte, Germany 
Tris-glycine SDS running buffer Invitrogen, Karlsruhe, Germany 
Triton X-100 Sigma Aldrich, Steinheim, Germany 
Trizma hydrochloride Sigma Aldrich, Steinheim, Germany 
Tween 20 Sigma Aldrich, Steinheim, Germany 
      
Table 2: Chemicals 
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2.2 Molecular biology 
Standard methods of molecular biology were performed according to Sambrook and 
Russell (157), if not stated otherwise. 
 
2.2.1 Cloning of promoter fragments or genes  
In general, amplified or digested DNA fragments were separated by size using agarose 
gel electrophoresis (1 to 3 % (w/v), (depending on fragment size); agarose; 1 x TAE; 0.5 
mg/ml ethidium bromide; 1 x TAE electrophoresis buffer). To isolate DNA fragments from gel 
or to purify PCR amplificants the QIAquick Gel Extractions-Kit (Qiagen, Hilden, Germany) 
was used according to manufacturer’s instructions.  
The ligation of purified DNA into a vector was mediated by 12 U T4-DNA-Ligase high 
concentration (Invitrogen, Karlsruhe, Germany) at room temperature for 30 minutes, or 
alternatively at 16°C over night with an insert:vector molar ratio of 3:1 and followed by the 
transformation into chemically competent Escherichia coli (E. coli), growing on ampicillin 
containing LB agar plates. Competent E. coli DH5α cells were prepared according to a 
standard protocol (158) and used for heat shock transformation of plasmid DNA (30 min on 
ice; 40 sec at 42°C; 1h at 37°C in 300 µl S.O.C medium (Invitrogen, Karlsruhe, Germany).  
To analyze for the presence of correct target plasmid DNA, recombinant bacterial 
colonies were screened with the CloneChecker System (Invitrogen, Karlsruhe, Germany) 
according to manufacturer’s instructions. For the isolation of the plasmid DNA from 
transformed E. coli colonies a bacteria suspension of 50 ml LB-medium (Midirep-Kit) or 3 ml 
LB-medium (Miniprep Kit) was incubated at 37°C overnight. The preparation of plasmid DNA 
from transformed E. coli colonies was performed using PureLink HiPure Plasmid DNA 
Midiprep, or PureLink HiPure Plasmid Miniprep Kit (Invitrogen, Karlsruhe, Germany) 
according to manufacturer’s instructions.  
 
2.2.2 Cloning plasmid constructs 1, 2 and 6 
Main promoter elements of plasmid constructs 1, 2 and 6 were generated by gene 
synthesis from Sloning Biotechnology, Puchheim, Germany. Following fragments (Table 3) 
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were generated by fusion PCR with primers that are listed in table 4. The fusion products, such 
as Fusion PCR synthetic1.1, Fusion PCR synthetic2.1 and Fusion PCR synthetic6.1 were 
digested each with FseI/StuI and cloned into the FseI- and StuI- sites of the final_synth1.1-
vector (product from TaconicArtemis GmbH) containing an F3 site, 5´Dneo, pAhGH, zs green 
gene, loxP site, tet operator, shLacZ, Caggs promoter and a LacZ gene, flanked by an FRT site. 
The plasmids were now termed new_synth1.1, new_synth2.1 and new_synth6.1, respectively. 
These plasmid were transformed subsequently into the Cre expressing E. coli strain 294-Cre 
(159) for Cre mediated deletion of PIE, resulting in constructs named new_synth1.1dPIE, 
new_Synth2.1dPIE and new_Synth6.1dPIE, respectively. 
 
Construct Description Sequence  
Fusion PCR 
synthetic1.1 
 
PCR1 was generated from 
the plasmid MRbasic with 
primers MR22s/oMR17as 
(341 bp); PCR2 was 
generated from 
final_synth1 with primers 
oMR21s/oMR19as (759 
bp). For the fusion of 
PCR1 and PCR2, primers 
oMR22s and oMR19as 
(1121 bp) were used. (All 
PCRs were performed with 
High Fidelity Platinum 
Taq Polymerase) 
GCGTTGGGTCCACTCAGTAGATGCCTGTTGAATTAAGCTTATTTA
AATAGGCCGGCCAGATCTGTCGACAATTGGATCCTCACAGTAGGT
GGCATCGTTCCTTTCTGACTGCCCGCCCCCCGCATGCCGTCCCGC
GATATTGAGCTCCGAACCTCTCGCCCTGCCGCCGCCGGTGCTCCG
TCGCCGCCGCGCCGCCATGGAATTCGAACGCTGACGTCATCAACC
CGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACC
CAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGG
GGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGA
AATCACCATAAACGTGAAATAACTTCGTATAATGTATGCTATACG
AAGTTATTTTTTGCGTTAATTAAGTGCGATTAAGGGTGCAGCGGC
CTCCGCGCCGGGTTTTGGCGCCTCCCGCGGGCGCCCCCCTCCTCA
CGGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGGAGCGTTCCT
GATCCTTCCGCCCGGACGCTCAGGACAGCGGCCCGCTGCTCATAA
GACTCGGCCTTAGAACCCCAGTATCAGCAGAAGGACATTTTAGG
ACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTTCCAGAGAG
CGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGG
AGGGATCTCCGTGGGGCGGTGAACGCCGATGATTATATAAGGAC
GCGCCGGGTGTGGCACAGCTAGTTCCGTCGCAGCCGGGATTTGG
GTCGCGGTTCTTGTTTGTGGATCGCTGTGATCGTCACTTGGTGAGT
TGCGGGCTGCTGGGCTGGCCGGGGCTTTCGTGGCCGCCGGGCCGC
TCGGTGGGACGGAAGCGTGTGGAGAGACCGCCAAGGGCTGTAGT
CTGGGTCCGCGAGCAAGGTTGCCCTGAACTGGGGGTTGGGGGGA
GCGCACAAAATGGCGGCTGTTCCCGAGTCTTGAATGGAAGACGC
TTGTAAGGCGGGCTGTGAGGTCGTTGAAACAAGGTGGGGGGCAT
GGTGGGCGGCAAGAACCCAAGGTCTTGAGGCCTTCGCTAATGCG
GGAAAGC 
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Fusion PCR 
synthetic2.1 
PCR1 was generated from 
the plasmid MRbasic with 
primers MR22s/oMR17as 
(341 bp); PCR2 was 
generated from 
final_synth2 with primers 
oMR21s/oMR19as (759 
bp). For the fusion of 
PCR1 and PCR2, primers 
oMR22s and oMR19as 
(1121 bp) were used. (All 
PCRs were performed with 
High Fidelity Platinum 
Taq Polymerase) 
GCGTTGGGTCCACTCAGTAGATGCCTGTTGAATTAAGCTTATTTA
AATAGGCCGGCCAGATCTGTCGACAATTGGATCCTCACAGTAGGT
GGCATCGTTCCTTTCTGACTGCCCGCCCCCCGCATGCCGTCCCGC
GATATTGAGCTCCGAACCTCTCGCCCTGCCGCCGCCGGTGCTCCG
TCGCCGCCGCGCCGCCATGGAATTCGAACGCTGACGTCATCAACC
CGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACC
CAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGG
GGAGTGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTGGGA
AATCACCATAAACGTGAAATGTCTTATAACTTCGTATAATGTATG
CTATACGAAGTTATTTTTTGCGTTAATTAAGTGCGATTAAGGGTG
CAGCGGCCTCCGCGCCGGGTTTTGGCGCCTCCCGCGGGCGCCCCC
CTCCTCACGGCGAGCGCTGCCACGTCAGACGAAGGGCGCAGGAG
CGTTCCTGATCCTTCCGCCCGGACGCTCAGGACAGCGGCCCGCTG
CTCATAAGACTCGGCCTTAGAACCCCAGTATCAGCAGAAGGACA
TTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTTC
CAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGAT
TCTGCGGAGGGATCTCCGTGGGGCGGTGAACGCCGATGATTATAT
AAGGACGCGCCGGGTGTGGCACAGCTAGTTCCGTCGCAGCCGGG
ATTTGGGTCGCGGTTCTTGTTTGTGGATCGCTGTGATCGTCACTTG
GTGAGTTGCGGGCTGCTGGGCTGGCCGGGGCTTTCGTGGCCGCCG
GGCCGCTCGGTGGGACGGAAGCGTGTGGAGAGACCGCCAAGGGC
TGTAGTCTGGGTCCGCGAGCAAGGTTGCCCTGAACTGGGGGTTGG
GGGGAGCGCACAAAATGGCGGCTGTTCCCGAGTCTTGAATGGAA
GACGCTTGTAAGGCGGGCTGTGAGGTCGTTGAAACAAGGTGGGG
GGCATGGTGGGCGGCAAGAACCCAAGGTCTTGAGGCCTTCGCTA
ATGCGGGAAAGC 
Fusion PCR 
synthetic6.1 
PCR1 was generated from 
the plasmid MRbasic with 
primers MR22s/oMR20as 
(339 bp); PCR2 was 
generated from 
final_synth6 with primers 
oMR21s/oMR19as (759 
bp). For the fusion of 
PCR1 and PCR2, primers 
oMR21s and oMR19as 
(1090 bp) were used. (All 
PCRs were performed with 
High Fidelity Platinum 
Taq Polymerase) 
GCGTTGGGTCCACTCAGTAGATGCCTGTTGAATTAAGCTTATTTA
AATAGGCCGGCCAGATCTGTCGACAATTGGATCCTCACAGTAGGT
GGCATCGTTCCTTTCTGACTGCCCGCCCCCCGCATGCCGTCCCGC
GATATTGAGCTCCGAACCTCTCGCCCTGCCGCCGCCGGTGCTCCG
TCGCCGCCGCGCCGCCATGGAATTCGAACGCTGACGTCATCAACC
CGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAACACC
CAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAGG
GGAGTGGCGCCCTGCAATATTTGCATTAGAGAATAACTTCGTATA
ATGTATGCTATACGAAGTTATTTTTTGCGTTAATTAAGTGCGATTA
AGGGTGCAGCGGCCTCCGCGCCGGGTTTTGGCGCCTCCCGCGGGC
GCCCCCCTCCTCACGGCGAGCGCTGCCACGTCAGACGAAGGGCG
CAGGAGCGTTCCTGATCCTTCCGCCCGGACGCTCAGGACAGCGGC
CCGCTGCTCATAAGACTCGGCCTTAGAACCCCAGTATCAGCAGAA
GGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTT
CTTTCCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCG
GCGATTCTGCGGAGGGATCTCCGTGGGGCGGTGAACGCCGATGA
TTATATAAGGACGCGCCGGGTGTGGCACAGCTAGTTCCGTCGCAG
CCGGGATTTGGGTCGCGGTTCTTGTTTGTGGATCGCTGTGATCGT
CACTTGGTGAGTTGCGGGCTGCTGGGCTGGCCGGGGCTTTCGTGG
CCGCCGGGCCGCTCGGTGGGACGGAAGCGTGTGGAGAGACCGCC
AAGGGCTGTAGTCTGGGTCCGCGAGCAAGGTTGCCCTGAACTGG
GGGTTGGGGGGAGCGCACAAAATGGCGGCTGTTCCCGAGTCTTG
AATGGAAGACGCTTGTAAGGCGGGCTGTGAGGTCGTTGAAACAA
GGTGGGGGGCATGGTGGGCGGCAAGAACCCAAGGTCTTGAGGCC
TTCGCTAATGCGGGAAAGC 
 
Table 3: Fusion PCR-synthetic1.1, -synthetic2.1 and –synthetic6.1  
 
 
 
 
 
 
 
  Material and Methods 
 
 31 
Primer Sequence (5´-3´) Tannealing °C Orientation 
oMR17 as GGTGATTTCCCAGAACACATAGCG 58 antisense 
oMR18 s CGCTATGTGTTCTGGGAAATCACC 58 sense 
oMR19 as GCTTTCCCGCATTAGCGAAGG 58 antisense 
oMR20 as ATGCAAATATTGCAGGGCGCCACTCC 58 antisense 
oMR21 s CGCCCTGCAATATTTGCATTAGAGAATAA
CTTCG 
58 sense 
oMR22 s GCGTTGGGTCCACTCAGTAGATGC 58 sense 
 
Table 4: Primers used for fusion PCR-synthetic1.1, -synthetic2.1 and -synthetic6.1 
All primer sequences are displayed in 5´-3´order. Primer orientation is designated "sense" when coinciding with 
transcriptional direction. All primers were purchased from Metabion, Germany. 
 
2.2.3 Cloning plasmid constructs 3, 4, 5 and 7 
The technical challenge was to insert a loxP site at any position within the promoter 
sequence. Therefore, the In-Fusion™Dry-Down PCR Cloning Kit (Clontech Laboratories, 
Saint-Germain-en-Laye, France) was used to amplify the required sequence by PCR reaction 
without the need of restriction enzymes cleavage. The amplified products contained 15 bp 
sequence homologies on both ends that were added through the PCR primers. Finally, the In-
Fusion Enzyme promoted single-strand annealing reactions between the DNA molecules that 
share short sequence overlaps (or homologies) at their ends, such as the PCR amplified insert 
and vector backbone. A schematic overview of the In-Fusion cloning method is depicted in 
Figure 4. 
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PCR product from plasmid SN1.0
PCR product from plasmid (MRbasic)
In fusion enzyme
Recombinant vector
 
Figure 3: Overview of Infusion cloning method  
The In-fusion enzyme creates single-stranded regions at the end of the vector and PCR product, which are then 
fused due to the 15 bp homology. Adapted from In-Fusion Dry-Down PCR Cloning Kit User Manual (Clontech 
Laboratories Inc.)  
 
PCR fragments were amplified from plasmids MRbasic and SN1.0 (both product from 
TaconicArtemis GmbH), respectively and fused using the In-Fusion™Dry-Down PCR Cloning 
Kit (Clontech Laboratories, Saint-Germain-en-Laye, France). The primers used for 
amplification are listed below (Table 5). PIE was deleted by Cre-mediated recombination 
through transformation of the plasmids into the Cre expressing E. coli strain 294-Cre (159). 
 
  
Construct Primer Sequence (5´ - 3´) Tannealing °C Description 
oMR2 s TTATAAGTCCCTATCAGTGATAGAGATT
CCCAGTG 
oMR2 as ATTTCACGTTTATGGTGATTTCCCAGAA
CACATAGC 
60 (4 x cycles) 
65 (16 x cycles) 
Used for amplification 
of the vector backbone 
consisting of following 
elements: F3, D-5´neo-
pA, pAhGH, defined 
parts from 5´ and 3´ of 
H1 promoter, FRT and 
amp resistance gene. 
Template plasmid: 
MRbasic;  Size: 5.72kb 
 
 
 
 
3 
oMR1 s AATCACCATAAACGTGAAATCGTATAA
TGTATGCTATACGAAGTTATGCGTAATA
CGACTCACTATAGGGCG 
55 (4 x cycles) 
65 (16 x cycles) 
Used for amplification 
of the H1 promoter 
elements implying a 
loxP flanked stuffer 
sequence called PIE 
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oMR1 as TCTCTATCACTGATAGGGACTTATAAGT
ATAGCATACATTATACGAAGTTATCTGT
TATCCCTAGCGTAACTGGC 
oMR8 s ATAAGTCCCTATCAGTGATAGAGATTCC
CAGTGGATGGAGCCG 
oMR8 as GGTGATTTCCCAGAACACATAGCGACA
TGC 
60 (4 x cycles) 
65 (16 x cycles) 
Used for amplification 
of the vector backbone 
consisting of following 
elements: F3, D-5´neo-
pA, pAhGH, defined 
parts from 5´ and 3´ of 
H1 promoter, FRT and 
amp resistance gene. 
Template plasmid: 
MRbasic;  Size: 5.71 kb 
oMR7 s ATGTGTTCTGGGAAATCACCATAACTTC
GTATAATGTATGCTATACGAAGTTATGC
GTAATACGACTCACTATAGGGCG 
 
 
 
 
4 
oMR7 as CTATCACTGATAGGGACTTATAATAACT
TCGTATAGCATACATTATACGAAGTTAT
CTGTTATCCCTAGCGTAACTGGCGCGC 
60 (4 x cycles) 
65 (16 x cycles) 
 
Used for amplification 
of the H1 promoter 
elements implying a 
loxP flanked stuffer 
sequence called PIE 
(zsgreen under control 
of an ubiquitin 
promoter). 
Template plasmid: 
SN1.0;     Size: 2.44 kb 
oMR10 s GCTATACGAAGTTATTGCAGTTTTAAAA
TTATGTTTTAAAATGGACTATCATATGC
TCACCATAAACGTGAAATGTCTTTGGAT
TTGGGAATCTTATAAGTCC 
oMR10 as TATTTTGTACTAATATCTTTGTGTTTACA
GTCAAATTAATTCTAATTATCTCTCTAA
CAGCCTTGTATCGTATATGCAAATATTG
CAGGGCGCCACTCCCCTGTC 
60 (4 x cycles) 
65 (16 x cycles) 
Used for amplification 
of the vector backbone 
consisting of following 
elements: F3, D-5´neo-
pA, pAhGH, defined 
parts from 5´ and 3´ of 
H1 promoter, FRT and 
amp resistance gene. 
Template plasmid: 
MRbasic;  Size: 5.85 kb 
oMR9 s CAAAGATATTAGTACAAAATAATAACT
TCGTATAATGTATGCTATACGAAGTTAT
GCGTAATACGACTCACTATAGGGCGAA
TTGGAGCTCCACCGCG 
 
 
 
 
5 
oMR9 as CTGCAATAACTTCGTATAGCATACATTA
TACGAAGTTATCTGTTATCCCTAGCGTA
ACTGGCG 
60 (4 x cycles) 
65 (16 x cycles) 
 
Used for amplification 
of the U6 promoter 
DSE element including 
a 156 bp promoter 
sequence 3´from U6-
DSE with the loxP 
flanked stuffer  
sequence called PIE 
(zsgreen under control 
of an ubiquitin 
promoter) and the PSE 
element from H1 
promoter.  
Template plasmid: 
SN1.0;      Size: 2.42 kb 
 
 
 
 
7 
oMR14 s TCATATGTCACCATAAACGTGAAATGTC
TTTGGATTTGGG 
58 (4 x cycles) 
65 (16 x cycles) 
 
Used for amplification 
of the vector backbone 
consisting of following 
elements: F3, D-5´neo-
pA, pAhGH, defined 
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oMR14 as TTTCCCAGAACACATAGCGACATGCAA
ATATTGCAGG 
oMR13 s GCATGTCGCTATGTGTTCTGGGAAATAG
AGAATAACTTCGTATAATGTATGCTATA
CGAAGTTATGCGTAATACG 
oMR13 as CACGTTTATGGTGACATATGAATAACTT
CGTATAGCATACATTATACGAAGTTATC
TGTTATCCCTAGCGTAACTGGCGCG 
58 (4 x cycles) 
65 (16 x cycles) 
 
Used for amplification 
of the H1 promoter 
elements implying a 
loxP flanked stuffer 
sequence called PIE 
(zsgreen gene under 
control of an ubiquitin 
promoter). 
Template plasmid: 
SN1.0;       Size: 2.45kb 
 
  
Table 5: Primers used for cloning of construct 3, 4, 5 and 7 
All primer sequences are displayed in 5´-3´order. Primer orientation is designated "sense" when coinciding with 
transcriptional direction. All primers were purchased from Metabion, Germany. 
  
 
2.2.4 Isolation of Genomic DNA 
For genomic DNA isolation, mouse tail biopsies were incubated overnight in lysis 
buffer (100 mM Tris-HCl (pH 8.5), 5 mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl, 200 µg/ml 
proteinase K) in a thermomixer (Eppendorf, Hamburg, Germany) at 55°C and 1100 rounds per 
minute (rpm).  Samples were centrifuged to discard debris and supernatant was transferred in a 
new vial. DNA-precipitation was then performed by addition of one equivalent of isopropanol. 
After centrifugation and a single washing step with 70% (v/v) ethanol, the DNA pellet was 
dried at room temperature (RT) for 15 minutes and resuspended in TE buffer (10 mM Tris-
HCL (pH 7.5), 1 mM EDTA (pH 8.0)).  
Mouse embryonic stem (mES) cells were incubated in lysis buffer (10 mM Tris-HCL 
(pH 7.5), 10 mM EDTA, and 10 mM NaCl, 5% (w/v) N-Laurylsacrosinate, 0.5 mg/ml 
proteinase K) at 60°C over night.  DNA was precipitated with double amount of 100% ethanol, 
absolute, washed as described above and resuspended in double distilled water (ddH2O). 
 
2.2.5 Polymerase Chain Reaction (PCR) 
The PCR method (160, 161) was used to genotype the mice for the presence of 
transgenes with customized primers listed in table 6. Reactions were performed in a 
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thermocycler MultiCycler PTC 225 Tetrad (Bio-Rad Laboratories, CA, USA) or in DNA 
engine Tetrad 2 Peltier Thermal Cycler (Bio-Rad Laboratories, München, Germany). All 
amplifications were performed in a total reaction volume of 50 µl, containing a minimum of 50 
ng template DNA, 5 µM of each primer, 10 mM  dNTP Mix, 50 mM MgCl, 10 x PCR buffer 
and 5 units/µl Taq DNA Polymerase (Invitrogen, Karlsruhe, Germany). Standard PCR 
programs started with 5 minutes (min) of denaturation at  95°C, followed by 35 cycles 
consisting of denaturation at 95°C for 30 seconds (sec), annealing at oligonucleotide-specific 
temperatures for 30 sec and elongation at 72°C for 1 min and  a final elongation step at 72°C 
for 10 min.  
For cloning procedures, the High Fidelity Platinum Taq Polymerase (Invitrogen, 
Karlsruhe, Germany) was used instead. 
 
Primer Sequence (5’ - 3’) TAnnealing °C Orientation 
oRNA46 TATGGGCTATGAACTAATGACCC 60  antisense 
oRNA48 CCATGGAATTCGAACGCTGACGTC 60 sense 
oMRseq31as  CGGCGCGTCCTTATATAATCATCG 60 antisense 
Cre1011_1 ACGACCAAGTGACAGCAATG 
 
60 sense 
Cre1011_2 CTCGACCAGTTTAGTTACCC 60 antisense 
Rosawt1114_1 CTCTTCCCTCGTGATCTGCAACTCC 
 
60 sense 
Rosawt1114_2 CATGTCTTTAATCTACCTCGATGG 
 
60 antisense 
Neo1012_1 TGCTCCTGCCGAGAAAGTATCCATC
ATGGC 
60 sense 
Neo1012_2 CGCCAAGCTCTTCAGCAATATCACG
GGTAG 
60 antisense 
LacZ1004_3 ATCCTCTGCATGGTCAGGTC 60 sense 
LacZ1004_3 CGTGGCCTGATTCATTCC 
 
60 antisense 
 
Table 6: Primers used for genotyping 
All primer sequences are displayed in 5´-3´order. Primer orientation is designated "sense" when coinciding with 
transcriptional direction. All primers were purchased from Metabion, Germany. 
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2.2.6 Southern Blot 
10 µg of genomic DNA were digested overnight at 37°C, with 40 U of HindIII or 
BamHI restriction enzyme (New England BioLabs GmbH, Frankfurt, Germany) and separated 
electrophoretically on a 0.8% (w/v) agarose gel at 90 V. The DNA was subsequently 
transferred to a HybondTM-XL nylon membrane (GE Healthcare, Freiburg, Germany) by an 
alkaline capillary transfer (162). After a washing step with 2 x SSC, DNA was crosslinked to 
the membrane by baking at 80°C for 1 hr. The membrane was pre-hybridized at 65°C for 1 h in 
hybridization solution (1 M NaCl; 50 mM Tris-HCL (pH 7.5), 10% (w/v) dextran sulfate, 0.1% 
(w/v) SDS; 250µg/ml sonicated salmon sperm DNA). The probes were generated by digestion 
of vector plasmid DNA or by PCR (Table 7, 8) and labeled with α-32P-dCTP (PerkinElmer Life 
Sciences, Köln, Germany) using the Amersham Ready-To-Go DNA labeling beads (GE 
Healthcare, Freiburg, Germany). The radioactively labeled probe was then added to the pre-
hybridization solution and hybridization was performed overnight at 65°C in a rotating 
cylinder. Un-specifically bound probe was removed by washing the membrane initially with 2 
x SSC / 0.1 % (w/v) SDS, followed by 0.2 x SSC / 0.1% (w/v) SDS, if necessary. All washes 
were performed at 65°C under gentle shaking for 10-20 min. After each wash, the membrane 
was monitored with a scintillation detector and the washing steps were stopped when 
radioactivity reached 20 to 50 impulses per second (IPS). The membrane was then sealed in a 
plastic bag and exposed to autoradiography film (Kodak BioMax, MS; Sigma-Aldrich Chemie 
GmbH, Deisenhofen, Germay) at -80°C. Films were developed in an automatic developer 
(Agfa HealthCare GmbH, Köln, Germany).  
  
 
Probe  Size (bp) Restriction enzyme Vector Description 
Rosa 3´ 386 HindIII JS43   external probe 3´ 
from integration site 
at the rosa26 locus 
Neo  519 HindIII/ EcoRI KD602 Internal probe 
Puro 292 SpeI/XhoI  pMultilink 
Puro 
Internal probe 
 
Table 7: Probes for Southern Blot generated by digestion of vector DNA  
The vectors are all products from TaconicArtemis GmbH.  
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Probe Size 
(bp) 
Primer (5´-3´) Tannealing °C Orientation Plasmid Description 
AAGGATACTGGGGCA
TACG 
 
60              sense 
 
Rosa 5´ 533 
CTTCTCAGCTACCTTT
ACACACC 
60 antisense 
JS32 External 
probe   5´ 
from 
integration 
site at the 
rosa26 
locus 
 
Table 8: Probes for Southern Blot generated by PCR 
All primer sequences are displayed in 5´-3´order. Primer orientation is designated "sense" when coinciding with 
transcriptional direction. All primers were purchased from Metabion, Germany. 
                                            
2.2.7 RNA Extraction and Quantitative Realtime-PCR (qPCR) 
Total RNA from murine cells and tissues was extracted using the Qiagen RNeasy Plus 
Mini Kit (Qiagen, Hilden, Germany). 1 µg of each RNA sample was reversely transcribed 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystem, Darmstadt, 
Germany) according to manufacturer’s instructions. The analysis was performed using the ABI 
Prism 7900HT Fast Real-time PCR System (Applied Biosystems, Foster City, USA). The 
probes used during this work are listed in table 9, 10 and 11. Samples were adjusted for total 
RNA content to heterochromatin protein 1, binding protein 3 (Hp1bp3) and mouse 
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) RNA. Quantification of relative cDNA 
transcript amounts was calculated by comparative method (2-∆∆Ct). Data were analyzed with the 
Sequence Detector System (SDS) software version 2.1 (ABI) and Ct value was automatically 
converted to fold change RQ value ((RQ) = 2-∆∆Ct). The RQ values from each gene were then 
used to compare the gene expression across all groups.  
 In brief, the threshold cycle value (Ct) is the fractional PCR cycle number at which the 
fluorescent signal reaches the detection threshold. Therefore, the input cDNA copy number and 
Ct are inversely related. The higher the initial amount of the sample, the sooner the 
accumulated product is detected in the PCR process as a significant increase in fluorescence, 
and the lower is the Ct value.  
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Probe  Catalogue N° 
Sirt2   Mm00452114_m1 
Sirt1 Mm00490758_m1 
PPARγ Mm00440940_m1 
HP1bp3 Mm00802807_m1 
Mouse GAPDH Endogenous Control (VIC®/MGB 
Probe, Primer Limited) 
 
Table 9: Real-Time analysis probes 
 
Target RNA Primer 5´ Primer 3´ Probe 5´-3´ 
LacZ  CTGTATGTGGTGGAT
GAAGCCAATA 
 
CGCGGATCATCGGT
CAGA 
ATGCCGTGGGTT
TCA 
 
Table 10: Custom Real-Time analysis probes 
 
Target shRNA Strand of shRNA Sequence 5´-3´ for assay design 
shLacZ2 antisense UUCAAUAUUGGCUUCAUCCAC 
 
Table 11: Custom Real-Time analysis probes for small RNA   
 
2.2.8 DNA sequencing  
DNA-sequencing was performed using Big Dye Termination v3.1 Cycle Sequencing 
Kits (Applied Biosystems, Darmstadt, Germany). Therefore 1.0 µl Ready Reaction Premix 
(2.5x), 3.0 µl BigDye Sequencing Buffer (5x), 2.0 pmol/µl Primer and 400 ng dsDNA were 
adjusted to a final volume of 10 µl and submitted to 25 cycles of the following temperature 
program: 30 sec at 96°C; 20 sec at 55°C; 2 min at 60°C. The fluorescently labeled DNA 
fragments were purified by a filtration step using Sephadex TM G-50 Medium (GE Healthcare 
Bio-science, Freiburg, Germany) before the sequence was automatically determined with the 
ABI Prism 3130xl Genetic Analyzer. The evaluation was performed with the software 
Sequencher 4.9 (Gene Codes Corporation, Ann Arbor, USA).  
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2.2.9 Quantification of DNA and RNA  
Nucleic acid concentration was assessed by measuring the sample absorption at 260 nm 
with a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Peqlab, Erlangen, Germany). The 
260/280 nm absorbance ratio was used as a measure of purity for nucleic acid samples. A ratio 
of ~1.8 was accepted as pure DNA and a ratio of ~2.0 as pure RNA.  
 
2.2.10 Protein extraction 
Snap-frozen tissues were disrupted in organ lysis buffer (50 mM HEPES (pH7.4), 1% 
(v/v) Triton X-100,  50 mM sodium chloride, 10 mM EDTA, 0.1% (w/v) SDS, protease 
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitor 
cocktail (Roche Diagnostics, Mannheim, Germany)) at 3 ml/g tissue and homogenized by the 
usage of a TissueLyser II (Qiagen, Hilden, Germany) for 2 min at 30 Hz using 5 mm stainless 
steel beads (Qiagen, Hilden, Germany). Particulate matter was removed by centrifugation for 1 
h at 4°C. The supernatant was transferred to a fresh vial. Adipose tissue was centrifuged for a 
second time to get rid of the fat layer. The protein concentration was determined according to 
manufacturer’s protocol (Pierce BCA protein assay kit; Fisher Scientific, Schwerte, Germany). 
Protein extracts were diluted to 2.5 mg/ml with organ lysis buffer and 4 x SDS sample butter 
(250 mM Tris-HCL (pH 6.8), 200 mM DTT, 8% (w/v) SDS, 40% (v/v) glycerol, and 0.04% 
(w/v) bromophenol blue), incubated at 95°C over 5 min and stored at -80°C 
 
2.2.11 Western Blot 
Protein lysates were thawed, centrifuged and supernatant was separated on a 4-12% 
Novex® Tris-Glycine polyacrylamide gel (Invitrogen, Karlsruhe, Germany) with 1 x SDS 
running buffer (163) and blotted onto nitrocellulose membranes (Invitrogen, Karlsruhe, 
Germany). Membranes were then blocked with 5% (w/v) BSA in 1x TBS, 0.1% (v/v) Tween20 
or with 5% (w/v) non-fat milk in 1x TBS/0.1% (v/v) Tween, depending on the usage of the 
antibody, for 1h at RT. Subsequently, primary antibodies (Table 12) were diluted in freshly 
prepared blocking solution as described above and incubated overnight at 4°C. Nitrocellulose 
membranes were then washed three times for 5 min with 1 x TBS/0.01% (v/v) Tween. After 1 
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h incubation at RT with the respective secondary antibody, membranes were washed 3 times 
for 5 min with 1 x TBS/0.01% (v/v) Tween and incubated for 5 min in Pierce ECL Western 
Blotting Substrate (VWR international GmbH, Langenfeld, Germany), sealed in a plastic bag 
and exposed to chemiluminescence film (Kodak BioMax MS; Sigma-Aldrich Chemie GmbH, 
Deisenhofen, Germay). Films were developed in an automatic developer (Agfa HealthCare 
GmbH, Köln, Germany). 
 
Antibody Catalogue No Distributor Dilution 
Sirt2 Sc-20966 Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
1:1000 
Akt 9372 Cell Signaling, (NEB 
Biolabs, Frankfurt, 
Germany) 
1:1000 
 
Table 12: Antibodies used for western blot analysis 
 
2.2.12 Enzyme-linked Immunosorbent Assay (ELISA) 
 Serum insulin and leptin were measured by ELISA using mouse standards according to 
the manufacturer’s guidelines (Mouse Leptin ELISA, #90030, Crystal Chem., Downers Grove, 
IL, USA; Rat Insulin ELISA, #INSKR020, Crystal Chem., Downers Grove, IL, USA) 
 
2.3 Histological analysis  
White adipose tissue of high fat diet (HFD) and normal chow diet (NCD) induced 
control+dox and shSirt2-2+dox transgenic mice was dissected, fixed overnight in 4% (w/v) PFA 
(Sigma Aldrich, Seelze, Germany) and then embedded for paraffin sections. Subsequently, 7 µm 
thin sections were deparaffinized and stained with hematoxylin and eosin (H&E) for general 
histology. H&E (Sigma Aldrich, Seelze, Germany) staining was performed according to standard 
protocols. Quantification of adipocyte size was performed using AxioVision 4.2 (Carl Zeiss 
MicroImaging GmbH, Oberkochen, Germany). 
2.4 Cell culture 
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2.4.1 Embryonic stem cell lines 
The embryonic stem cell lines used in this work are listed in Table 13. 
 
ES cell line Strain Origin description 
Art4.12 B6129S6F1 TaconicArtemis 
GmbH 
Hybrid ES cell 
line 
F1 RMCE B6129S6F1-
Gt(ROSA)26Sortm9(Flpe-
RMCE) 
TaconicArtemis 
GmbH 
Implies an RMCE 
targeting system at 
the rosa26 locus. 
Targeted ES cells 
include: zsgreen, 
PGK-Hygro, 
CAGGS-Flpe  
B6/3.5 C57BL/6NTac TaconicArtemis 
GmbH 
Hybrid ES cell 
line 
ArtB6 RMCE 1011 C57BL/6NTac- 
Gt(ROSA)26Sortm9(Flpe-
RMCE) 
TaconicArtemis 
GmbH 
Implies an RMCE 
targeting system at 
the rosa26 locus. 
Targeted ES cells 
include: zsgreen, 
PGK-Hygro, 
CAGGS-LacZ  
Art4.12tt4RNA226 
neo del 
B6129S6F1 TaconicArtemis 
GmbH 
RMCE targeting 
system (zsgreen, 
PGK-Hygro, 
CAGGS Flpe) and 
a dual reporter 
system including 
Firefly and Renilla 
luciferase 
transgenes (Fluc, 
CAGGS Rluc, FRT 
flanked Neomycin) 
at the rosa26 locus.  
Subsequent deletion 
of the neomycin 
selection marker 
resulted by FLP as 
described in (164) 
 
Table 13: Embryonic stem cell lines at TaconicArtemis GmbH 
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2.4.2 Embryonic stem cell culture 
Culture and targeted mutagenesis of the hybrid ES cell line Art4.12 or B6 were carried 
out as previously described (164, 165). ES cells were cultured on a layer of mitomycinC-
treated primary feeder fibroblasts. The ES cell medium for Art4.12 ES cells contains D-MEM 
with 15% fetal calf serum (FCS), 1x non essential amino acids (MEM), 20 mM Hepes buffer,  
4 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM 2-β-mercaptoethanol and 1500 U/ml 
leukemia inhibitor factor (LIF) and ES cell media (20% media) for B6 ES cells contains D-
MEM with 20% fetal calf serum (FCS), 1 x non essential amino acids (MEM), 2 mM L-
glutamine, 1 mM sodium pyruvate, 20 mM Hepes, 0.1 mM 2-β-mercaptoethanol and 2000 
U/ml LIF. ES cells were grown in culture plates (Falcon, Bedford, USA) and kept at 37°C 
under humid atmosphere (95%) with 7.5% CO2. 
The medium was changed every day and ES cell colony growth was stopped before 
they became confluent, usually every 1-3 days. Then colonies were washed once with PBS and 
then treated shortly with trypsin (0.25% trypsin-EDTA, Gibco, Karlsruhe, Germany) at 37°C 
until the cells detached from the plate. The cells were resuspended in an appropriate volume of 
media and splitted (usually 1:3 – 1:6) onto fresh feeder dishes. 
ES cells were frozen in cryovials (Nunc, Wiesbaden, Germany) with 10% DMSO at -
80°C and transferred later into liquid nitrogen for long term storage.  
 
2.4.3 Transfection of ES cells with the exchange vector 
One day before transfection, 2 x 105 ES cells were plated per well on a 6 well plate. 6 
µl Fugene6 Transfection Reagent (Roche; Catalog No. 1814443, Mannheim, Germany) was 
mixed with 100 µl serum free medium (optiMEM I with Glutamax-I Invitrogen; Catalog No. 
51985-035) and incubated for 5 min at room temperature. 100 µl of the Fugene6/OptiMEM 
solution was added to 2 µg circular exchange vector DNA (c=0.5 µg/µl) and 2 µg (c=0.5 
µg/µl) pCAGGS-flpe-ires-puro (56, 166) and incubated for 45 min at RT. This transfection 
complex was added drop wise to the medium and mixed by a circuiting movement. Fresh 
medium was added to the transfected cells at the following day. From day 2 on, the medium 
was changed daily, replaced by medium containing 250 µg/ml G418 (Geneticin, Invitrogen; 
Catalog No 10131-019) for Art4.12 ES cells or 200 µg/ml G418 for B6 ES cells. Seven days 
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after transfection, single clones were isolated by standard procedures as described (56, 167) 
and subsequently validated by Southern Blot analysis. 
  
2.4.4 Doxycycline (dox) treatment of ES cells 
Single ES cell clones were cultivated with ES cell medium containing 1 µg/ml 
doxycycline (Sigma-Aldrich, Deisenhofen, Germany) for 72 hours. 
 
2.4.5 Analysis of doxycycline content in mouse serum 
 ES cells, carrying a doxycycline inducible Fluc expression cassette were cultivated in a 
96 well plate. Blood serum was obtained by cardiac puncture immediately after animals have 
been sacrificed by CO2 anesthesia. Cotted blood samples were centrifuged at RT for 10 min 
and 3000g. 10 µl of each animal serum were added to the ES cells, containing 90µl of ES cell 
medium per well (96 well plate) and incubated overnight 37 °C under humid atmosphere 
(95%) with 7.5 % CO2. The cells were washed twice in PBS, lysed in 100 µl/well lysis reagent 
supplemented with protease inhibitors according to the manufacturer’s protocol (ß-
Galactosidase Reporter Gene Assay Kit, Roche Diagnostics, Mannheim, Germany) and shaken 
for 20 min at RT. To determine Fluc activity, 35 µl of cell lysate was mixed with 35 µl of 
Steady-Glo Solution (Steady-Glo Luciferase Assay System, Promega, Mannheim, Germany) 
on white OptiPlate-96 plates (PerkinElmer, Rodgau, Germany) and shaken for 10 min at RT. 
Fluc activity was measured using a Wallac 1420 Multilabel luminescence counter 
(PerkinElmer LAS, Rodgau-Jügesheim, Germany). Total protein was determined according to 
the manufacturer’s protocol (Pierce BCA protein assay kit; Fisher Scientific, Schwerte, 
Germany) and adjusted to Fluc activity. 
 
2.4.6 ß-Galactosidase assay 
Ten days after transfection, targeted cells (Art4.12tt4RNA226 neo del) were incubated 
in 100 µl/well (96 well plate) lysis reagent supplemented with protease inhibitors according to 
the manufacturer’s protocol (ß-Galactosidase Reporter Gene Assay Kit, Roche Diagnostics, 
Mannheim, Germany) and shaken for 20 min at RT. 25 µl of cell lysate were mixed with 50 µl 
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of substrate reagent and 25µl of initiation solution (ß-Galactosidase Reporter Gene Assay Kit, 
Roche Diagnostics, Mannheim, Germany). The ß-galactosidase activity was determined using 
a Wallac 1420 Multilabel luminescence counter (PerkinElmer LAS, Rodgau-Jügesheim, 
Germany) and adjusted to Fluc activity. The Fluc activity measurement was performed as 
described in 2.4.5.  
 
2.5 Mouse experiments 
General animal handling was performed as described by Hogan and Silver  (167, 168). 
 
2.5.1 Animal care 
Mice were housed in a pathogen free facility at TaconicArtemis GmbH, Köln, Germany 
in isolated ventilated cages (TecniplastTM; Tecniplast Deutschland GmbH, Hohenpeißenberg, 
Germany) that provide a HEPA (Tecniplast Deutschland GmbH, Germany) filtered supply and 
exhaust air (99,97 %). Mice were kept at 21°C +/- 1°C on a 12 h light / 12 h dark cycle with 
the light on at 6 a.m. and were fed either a normal chow diet (NCD; Table 14) or a high fat diet 
(HFD; Table 14). All animals had access to water ad libitum. Food was only withdrawn if 
required for an experiment. At the end of the study period, animals were sacrificed by CO2 
anesthesia or cervical dislocation. All work was performed in accordance with the “Gesetz zur 
Regelung der Gentechnik” (GenTGS) October 2001 (German Biologic Act) and the 
Tierschutzgesetz 1998 (German Animal Welfare Act). Animal procedures and euthanasia were 
approved by the local government authorities (Bezirksregierung Köln) and were in accordance 
with National Institutes of Health guidelines. 
 
 
Animal food Diet Supplier Nutrient information 
TD.05298 
Teklad Global (2018) 
NCD Harlan Laboratories GmbH, 
Eystrup, Germany 
protein 18,2 %, 
carbohydrate 47,9 %, 
fat 5,8 % 
TD.05298 
Teklad Global (2018) 
NCD Harlan Laboratories GmbH, 
Eystrup, Germany 
protein 18,2 %, 
carbohydrate 47,9 %, 
fat 5,8 %, 1 g/kg Dox 
Ssniff EF R/M acc. F3282 HFD Ssniff Spezialdiäten GmbH, protein 20 %, 
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Table 14: Animal food 
 
2.5.2 Mice 
C57BL/6NTac mouse strains were ordered from Taconic. Chimeric mice or fully 
derived ES mice were generated at TaconicArtemis GmbH by injection of trypsinized 
recombinant ES cell clones into diploid or tetraploid blastocystes, respectively, and implanted 
into the uterus of a pseudogregnant mouse. The ES mice “shLacZU6/H1tetPIE” were mated 
with female “Art12rosaCre” mice that were obtained from the in-house facility of 
TaconicArtemis GmbH. Breeding colonies were maintained by mating “Art12rosaCre-
shLacZU6/H1tetPIE” (“shLacZU6/H1tet∆PIE”) with a constitutive expressing LacZ mouse 
strain (TaconicArtemis GmbH) to provide a reporter target for the LacZ specific shRNA 
expressed from the rosa26 locus. 
Chimeric “shSirt2-2U6/H1tetPIE” mice were mated with “Art12rosaCre” mice to 
achieve “Art12rosaCre-shSirt2-2U6/H1tetPIE” (“shSirt2-2U6/H1tet∆PIE”) mice expressing a 
Sirt2 specific shRNA from the rosa26 locus. 
All metabolic experiments were carried out with male “shSirt2-2H1tet” mice 
expressing a Sirt2 specific shRNA from the rosa26 locus. 
 
2.5.3 Body weight, blood collection and blood glucose levels  
Body weight was monitored weekly for 12 weeks. Blood glucose values were 
determined from whole venous blood of the tail using an automatic glucose monitor (Ascensia 
mod. Soest, Germany carbohydrate 35,7 %, 
fat 35,6 % 
Ssniff EF R/M acc. F3282 
mod. 
HFD Ssniff Spezialdiäten GmbH, 
Soest, Germany 
protein 20 %, 
carbohydrate 35,7 %, 
fat 35,6 %, 1 g/kg Dox 
Ssniff PS M-Z; S8289-
Po12 
NCD Ssniff Spezialdiäten GmbH, 
Soest, Germany 
protein 22,8 %, 
carbohydrate 32,5 %, 
fat 5,4 %,  
Ssniff PS M-Z; S8289-
Po12 
NCD Ssniff Spezialdiäten GmbH, 
Soest, Germany 
protein 22,8 %, 
carbohydrate 32,5 %, 
fat 5,4 %, 1 g/kg Dox 
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ELITE, Bayer Vital, Leverkusen, Germany). Collection of blood samples from living animals 
until a volume of 100 µl were obtained by submandibular puncture of the vena facialis. 
  
 2.5.4 Glucose and insulin tolerance test  
For glucose tolerance tests (GTT), mice were fasted overnight for 16 h. After 
determination of fasted blood glucose levels, each animal received an intraperitoneal injection 
of 20 % glucose solution (10 ml/kg body weight). Blood glucose was determined 15, 30, 60, 
and 120 min after injection. For insulin tolerance tests (ITT), each random fed animal was 
injected intraperitoneal with a 0.75 U/ml insulin solution (0.75 U/kg body weight) after 
determination of random fed blood glucose concentration. Blood glucose was determined 15, 
30 and 60 min after injection. 
 
2.5.5 Food intake and indirect calorimetry 
Daily food intake was measured over a period of 7 days and calculated as the average 
intake of chow over the time stated. Weight of food was determined every day. Calorimetry 
measurements were performed in a PhenoMaster System (TSE systems, Bad Homburg, 
Germany), which allows measurement of metabolic performance and activity-monitoring by an 
infrared light-beam frame. Mice were placed at RT (22°C–24°C) in 7.1-l chambers of the 
PhenoMaster open circuit calorimetry. Mice were allowed to adapt to the chambers for at least 
24 h. Food and water were provided ad libitum in the appropriate devices and measured by the 
build-in automated instruments. Locomotor activity and parameters of indirect calorimetry 
were measured for at least the following 48 h. Presented data are average values obtained in 
these recordings. 
 
2.5.6 Behavioral analysis 
Locomotor behavior of shSirt2-2 transgenic mice and littermate controls was 
determined by placing the animals in a rotarod apparatus with constant acceleration in 6 
consecutive trials of 5 minutes each. The time spent in the rotating rod was recorded for each 
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animal and trial until mouse fell off. Animals were familiarized with the procedure under 
constant rod speed 1 day earlier.  
 
2.5.7 MPTP treatment 
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) was obtained 
from Sigma (Sigma), dissolved in 0.9% saline and injected i.p. in a volume of 1 ml/100 g body 
weight. Control animals received an equivalent i.p. injection of saline. The animals received up 
to four injections of 20 mg/kg on 1 day, at 2 h interval, for a cumulative dose of 80 mg/kg. 
Locomotor behavior was performed one week after treatment with MPTP or saline, 
respectively. 
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3 Results 
3.1 Generation of Cre-mediated spatially and temporally regulated shRNA 
expression system 
To derive a system for conditional activation of shRNA expression, we aimed to insert 
a loxP flanked stuffer sequence into the promoter such that transcription is completely 
abrogated whereas Cre mediated deletion of the DNA segment will restore promoter activity. 
The stuffer sequence, referred as promoter inhibitory element (PIE), contains the constitutive 
expressed reporter gene (Zsgreen) that is driven by an ubiquitous promoter. Since full 
reactivation of transcription represents a critical aspect, we first tried to define a position within 
the regulatory elements (Figure 4A,B) in which a single loxP site is tolerated without a 
significant loss of promoter activity. In a second step, inhibition of shRNA expression in the 
presence of PIE was tested. 
 
3.1.1 The effect of a single loxP site on promoter activity in vitro 
To determine if the presence of the loxP site interferes with promoter activity, various 
configurations have been developed and classified in three groups mimicking the promoter 
region after Cre-mediated recombination event (Figure 4). In group 1, a single loxP site was 
positioned at different positions 5´ from TATA by substituting promoter sequences (Figure 4C-
F). In group 2, a loxP sequence was inserted at different positions between hH1 control 
elements (Figure 4H-I). Finally, a hybrid configuration consisting of human H1 (hH1) and 
human U6 (hU6) Pol III promoter elements was generated in group 3. Since there is 156 bp 
stuffer sequence 3´ from hU6-DSE element, promoter sequences were replaced by a single 
loxP site without altering the sequence and spacing of the regulatory elements (Figure 4G).  
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TCACCATAAACGTGAAAT TTATAAGTCTTTGGATTTGGGAATC
ATAACTTCGTATAATGTATGCTATACGAAGTTAT loxP
TCACCATAAACGTGAAAT TTATAAGTCTTTGGATTTGGGAATC
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Figure 4: Schematic overview of promoter configurations after Cre-mediated recombination  
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A) The human H1 promoter consists of DSE (-98 to -70), PSE (-69 to -52) and a TATA box (-32 to -27). The 
transition from SPH/PSE is seamless and Oct/SPH is separated by one nucleotide. B) The human U6snRNA gene 
consists of a distal sequence element (DSE,−225 to−247) that enhances transcription and a core promoter 
composed of a proximal sequence element (PSE,−68 to−49) and a TATA box  (−31to−26). The DSE is classified 
in two sequence elements, SPH and OCT. The promoter elements DSE/PSE are separated by 156 bps and 
PSE/TATA by 17 bps, respectively. C) A wt-loxP was integrated between PSE/TATA (hH1), whereas exact 
nucleotides, indicated by an asterisk, serve for both DSE/loxP and loxP/TATA (bold letters). D) Three non-
conserving nucleotides between PSE/TATA (hH1) were substituted by loxP. E) By mutating the loxP sequence, 
the spacing among PSE/TATA (hH1) was preserved. F) Nucleotides from PSE/TATA (hH1) were substituted by 
wt loxP site. Exact matching nucleotides are indicated by an asterisk. G) Hybrid H1/U6 promoter configuration 
including human U6 (hU6) DSE and the human H1 (hH1) PSE. Nucleotides within the 156 bp spacing region of 
DSE and PSE control elements were replaced by a single loxP-site.  H) A LoxP sequence was inserted between 
SPH and OCT (hH1). I) A LoxP sequence was inserted between DSE and PSE (hH1). 
 
 
However, all promoter configurations were tested by inserting a LacZ specific shRNA-
sequence and a LacZ expression cassette under the control of the ubiquitous CAGGS promoter 
(Figure 5A). Before introduction into the rosa26 locus by RMCE technology (56, 169) (Figure 
5A), the plasmids including floxed PIE were transformed into a Cre expressing E.  coli strain 
(159), removing PIE through recombination between the two loxP sites. ES cells carrying 
either a shRNA against LacZ or an irrelevant target (shRNA against insuline receptor), served 
as positive and negative controls, respectively. The shRNAs from both control constructs were 
driven each by a H1 promoter (Figure 5A, lower panel). Finally, the shLacZ expression levels 
were determined in ES cells by quantitative realtime PCR. As shown in Figure 5B, the 
strongest shLacZ expression amongst others could be observed for construct 5 (U6/H1tet 
system), demonstrating that the remaining loxP site allows activated gene silencing after Cre 
recombinated event.  
Next, further in vitro analyses were performed with construct 5 in the presence and 
absence of PIE (Figure 5E-F). Successful integration into the rosa26 locus using genomic 
DNA from transfected ES cells and an internal probe (puro) was demonstrated by Southern 
blot analysis (Figure 5C-D). As shown in Figure 5E, a knockdown of about 50% was noted for 
construct 5 after deletion of PIE compared to ~70% knockdown of the positive control 
consisting of a shLacZ driven by the unmodified H1 promoter. In contrast, the mRNA level of 
LacZ was not decreased in the presence of PIE. These results were confirmed as well on 
protein level using a ß-Galactosidase assay. Moreover, the data were comparable to controls 
with a knockdown efficiency of ~90% (Figure 5F). 
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Figure 5: Analysis of seven configurations at the rosa26 locus in mouse ES cells  
A) Stable integration of a single vector cassette into the modified rosa26 locus, called rosa26(RMCE), carrying 
the RMCE acceptor comprising Zsgreen, PGK-Hyg and CAAGS-FLP. The exchange vector carries the shRNA 
expression cassette under the control of the engineered promoter (here exemplify shown for construct5) with the 
single loxP site, the target gene lacZ under control of the CAGGS promoter and the F3/FRT pair. The RMCE by 
FLPe-mediated recombination generates the rosa26 (RMCE exchanged) allele. The truncated neoR gene allows 
for positive selection upon successful RMCE. The control constructs consist of a shRNA that is under control of 
the H1 promoter. (SA=splice acceptor) B) shLacZ expression levels were determined by quantitative realtime 
PCR in ES cells with a shLacZ expression control (pos.ctrl.), an  irrelevant shRNA expression control (shRNA 
against the insulin receptor; neg.ctrl.) and ES cells carrying the promoter modification including the single loxP 
site after PIE deletion (construct1-7, respectively; n=2 clones per group). C) Southern blot analysis of genomic 
DNA from transfected ES cells carrying the construct5 with the promoter inhibitory element (PIE). The sizes of 
rosa26 (RMCE) and rosa26 (RMCE exchanged) are 2.7 and 7.2 kb, respectively. In clones 2, 4-8 successful 
RMCE had occurred. Genomic DNA was digested with EcoRV (E) and analyzed using the puro probe (probe 1). 
D) Southern blot analysis of genomic DNA from transfected ES cells carrying the construct5∆PIE. The size of 
rosa26 (RMCE exchanged) is 4.8 kb. In clones 1, 3-6 successful RMCE had occurred. Genomic DNA was 
digested with EcoRV (E) and analyzed using the puro probe (probe 1). E) Quantitative realtime PCR analysis of 
targeted ES cells. LacZ mRNA expression level are shown from negative control (white bars; expression of 
shRNA against insuline receptor), positive control (white striped bars; constitutive expressing shLacZ), shLacZ 
U6/H1tetPIE (construct5PIE; black bars) and of shLacZ U6/H1tet∆PIE (construct5∆PIE). n=2. F) The ß-
Galactosidase activity of targeted ES-cells, harboring a dual reportergene system, was measured in relative light 
units [RLU] from a constitutive shLacZ expression control (pos.ctrl.), a constitutive,  irrelevant shRNA expression 
control (shRNA against the insulin receptor; neg.ctrl.) and cells carrying construct5PIE or construct5∆PIE, 
respectively. Firefly Luciferase activity was used for normalization. n=4 
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Taken together, data from ES cells carrying construct 5 have clearly shown 
transcriptional inactivation in the presence of PIE. After Cre mediated deletion of PIE, 
promoter activity was restored resulting in shRNA expression with a knockdown efficiency of 
60-90 %. Thus, next steps were performed with the modified promoter configuration of 
construct 5.  
 
3.1.2 Spatially and temporally activated RNAi of LacZ in mice by the hybrid Pol 
III  system 
To allow for doxycycline inducible activation of shRNA expression the LacZ coding 
region was replaced by a transgene encoding the E. coli tetracycline resistance operon 
repressor (tetR) (56) (Figure 6A). In the absence of dox, the tet repressor (tetR) binds to 
operator sequence (tetO) and thereby blocks shRNA transcription. Upon administration of dox, 
tetR is released and shRNA mediated gene silencing proceeds (Figure 6A). After RMCE 
mediated insertion of the U6/H1tetPIE configuration into the rosa26 locus, recombinant ES 
cells were injected into tetraploid blastocysts to achieve completely ES cell derived mice. For 
deletion of the loxP-flanked PIE element, shLacZ U6/H1tetPIE transgenic mice were further 
crossed to a Cre deleter mouse line (TaconicArtemis, unpublished), resulting in the shLacZ 
U6/H1tet∆PIE allele (Figure 6A). Mice carrying the standard inducible RNAi cassette were 
used as positive controls (Figure 6A, lower panel). Furthermore, shRNA transgenic mice were 
mated with constitutively expressing LacZ mice (TaconicArtemis, unpublished), to provide a 
reporter target for the LacZ specific shRNA.  
The knockdown level of LacZ was measured in different tissues by quantitative realtime 
PCR (Figure 6B). Constitutive expressing LacZ control mice (neg.ctrl.), shLacZ H1tet mice 
(pos.ctrl.), shLacZ U6/H1tetPIE mice and shLacZ U6/H1tet∆PIE mice were fed either with 
dox food or control food for 14 days, respectively. A down regulation of LacZ mRNA was 
achieved with shLacZ H1tet and shLacZ U6/H1tet∆PIE after induction with dox, but not in 
shLacZ U6/H1tetPIE mice, confirming that the promoter activity for shRNA expression is 
disrupted by PIE, even though the tetR is non-bound. No downregulation of LacZ mRNA 
could be observed in the un-induced state, except for brain of shLacZ H1tet and shLacZ 
U6/H1tet∆PIE mice, indicating that in this tissue, the promoter may show gene silencing. The 
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knockdown level of shLacZ U6/H1tet∆PIE mice was generally weaker (~ 30-40% in brain and 
kidney) compared to shLacZ H1tet control animals (~ 80% in EWAT, kidney, liver).  
To determine a fully deletion of PIE after Cre-recombination, Zsgreen mRNA was 
measured by quantitative realtime PCR in shLacZ U6/H1tetPIE, wildtype and in shLacZ 
U6/H1tet∆PIE mice (Figure 6C). The results show a presence of PIE in shLacZ U6/H1tetPIE 
mice whereas PIE is clearly disappeared in shLacZ H1/U6∆PIE mice after Cre-recombination, 
demonstrated in several tissues such as liver, brain and muscle (Figure 6C).  
In conclusion, Cre-mediated recombination of the floxed PIE cassette and induction 
with dox results in an activation of hybrid U6/H1tet promoter in vivo. Compared to the 
standard inducible shLacZ H1tet system, however, the knockdown of the activated shLacZ 
U6/H1tet∆PIE animals was 30-60 % weaker. Moreover, in several tissues such as EWAT and 
liver, no significant gene silencing was detected.  
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Figure 6: Schematic overview illustrating the activation of H1/U6 hybrid mediated gene silencing (A) and 
its analysis in vivo (B, C) 
A) A single loxP site was replaced by a loxP flanked cDNA cassette named PIE (promoter inhibitory element), 
consisting of the reporter gene Zsgreen that is under control of a human ubiquitin promoter and placed between 
the elements DSE (hU6) and PSE (hH1). The LacZ coding region was changed by an E. coli tetracycline 
resistance operon repressor (tetR) (upper panel). After stable integration into the rosa26 locus, PIE can be deleted 
through Cre-recombination, leaving in a single loxP site and an activation of the hybrid promoter (middle panel).  
Expression of shLacZ is still inhibited through binding of the tetR on tetO sequence. Only administration of dox 
lead to a conformational change of the tetR which then release from the tetO resulting in activated shRNA 
expression (lower panel). The standard inducible system was used as positive control where the shRNA (shLacZ) 
is driven by an inducible H1 promoter. B) LacZ mRNA expression levels were determined in different tissues by 
quantitative realtime PCR from constitutive LacZ expressing controls mice (white bars), shLacZ H1tet mice 
(black bars), shLacZ U6/H1tetPIE mice (grey striped bars) and shLacZ U6/H1tet∆PIE (black striped bars) mice, 
respectively. 12-20 weeks old mice were fed 14 days either with control or dox-food (1g/kg dox), indicated by a 
minus or plus. LacZ mRNA level of non-induced control mice (black bar) was set 100%; n=3 males. C) 
Successful Cre recombination was determined by the deletion of PIE. PIE represents the reporter gene Zsgreen 
that is under control of an ubiquitin promoter. Zsgreen mRNA expression levels were determined in different 
tissues by quantitative realtime PCR from wildtype control, shLacZ U6/H1tetPIE and shLacZ U6/H1tet∆PIE 
mice. 6-8 weeks old mice were induced for 10 days either with control drinking water or with drinking water 
supplemented with dox (2mg/ml), indicated by a minus or plus. Zsgreen mRNA expression was only measured 
before Cre recombination mediated event in the presence of PIE (black bars). Each bar indicates one female and 
on male, respectively (n=2).  Hp1bp3 mRNA was used as endogenous control. (All data are presented as mean ± 
SEM) 
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3.1.3 Spatially and temporally activated RNAi of Sirt2 in mice by the hybrid Pol 
III system 
To characterize the efficiency of the Pol III U6/H1tet system for silencing of an 
endogenous mouse target gene, Sirt2 was used for further knockdown studies. Altogether, five 
shRNAs were designed with an algorithm program used for the prediction of the shRNA 
functionality. After analyzing knockdown efficiency with the standard inducible H1-tet system 
in ES cells, two shRNAs (shSirt2-2 and shSirt2-6) with the highest RNAi efficiency (>80 %) 
were chosen for further studies (Figure 7A).  
The U6/H1tet hybrid configuration containing shSirt2-2 as well as controls constructs 
were integrated into the rosa26 locus of mouse ES cells by RMCE technology and validated 
subsequently. The knockdown of Sirt2 was investigated in vitro by quantitative realtime PCR 
(Figure 7B). Only after recombination of the floxed PIE element by Cre recombinase and in 
presence of dox, a knockdown of 80-90% of Sirt2 mRNA could be observed (#clone1 shSirt2-
2 U6/H1tet∆PIE; #clone2 shSirt2-2 U6/H1tet∆PIE). Importantly, the knockdown efficiency of 
induced shSirt2-2 U6/H1tet∆PIE carrying ES cells was comparable to control ES cells, 
harboring the standard inducible knockdown system (shSirt2-2 H1tet; grey bars). In contrast, 
no repression could be detected on samples with PIE configuration (black striped bars). To 
exclude that the confluence of the ES cells has an effect on Sirt2 mRNA expression levels, 
controls with a RMCE construct including a poly T stop signal instead of a shRNA (poly T 
control) were cultivated with high or low density, respectively (black bars) (Figure 7B). 
To translate these findings into an in vivo setting, chimeric mice (shSirt2-2 U6/H1tetPIE) 
were generated and crossed with a cre-deleter line resulting in progeny carrying the activated 
(shSirt2-2 U6/H1tet∆PIE) shRNA construct. In parallel, control mice were generated, 
harboring a tet-inducible shSirt2-2 expression cassette (shSirt2-2 H1tet). ∆PIE animals 
(shSirt2-2 U6/H1tet∆PIE), shSirt2-2 H1tet and wildtype control animals (C57BL/6NTac) were 
induced for 17 days with dox food and tissues were prepared for quantitative realtime PCR 
analysis, respectively. Compared to Sirt2 expression levels in C57BL/6NTac wildtype animals, 
a knockdown of ~80-90% could be achieved in heart, kidney and muscle and ~60-75% in liver, 
EWAT and brain of dox induced shSirt2-2 U6/H1tet∆PIE mice (grey striped bars) (Figure 7C). 
In the control group (shSirt2-2 H1tet; grey bars) a consistent repression of 90~95% was noted 
for all tissues evaluated. 
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Taken together, these results indicate that in vivo knockdown of Sirt2 caused by shSirt2-2 
U6/H1tet∆PIE is 3.6- to 5.4-fold weaker, compared to the shSirt2-2 H1tet system. Therefore, a 
further analysis of Cre inducible shSirt2-2 expression was not performed. 
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Figure 7: Knockdown level of Sirt2 in vitro and in vivo using the inducible hybrid H1/U6 system  
A) Five shRNAs, shSirt2-1 (grey bars), shSirt2-2 (black striped bars), shSirt2-3 (dark grey bars), shSirt2-5 (black 
bars) and shSirt2-6 (grey striped bars) against Sirt2, driven by a tet-inducible H1 promoter, were analyzed in ES 
cells to evaluate their knockdown efficiency. The knockdown level was determined by quantitative realtime PCR 
analysis of targeted ES cells in presence or absence of dox (1µg/ml, 72h induction; indicated by a minus or plus).  
The highest Sirt2 knockdown was reached with shSirt2-2 (black striped bars) and shSirt2-6 (grey striped bars). 
Further experiments are performed with shSirt2-2 whereas shSirt2-6 served as a control to rule out off-target 
effects. Control cells (white bars) containing a poly T signal were cultivated either with high or low confluence. 
GAPDH mRNA was used as endogenous control. B) Quantitative realtime PCR analysis of targeted ES cells 
which were induced with or without dox (1µg/ml) for 72h, indicated with plus or minus. Sirt2 mRNA expression 
level are shown from shSirt2-2 H1/U6-PIE (black striped bars), two ES cell clones of shSirt2-2 H1/U6∆PIE and 
shSirt2-2 H1 cells (grey bars). Control cells (white bars) containing a poly T signal were cultivated either with 
high or low confluence. GAPDH mRNA was used as endogenous control. C) Relative mRNA levels (wt control = 
100%) of tissues from wt control (white bar), shSirt2-2 H1 (grey bars) and shSirt2-2 H1/U6∆PIE (striped bars) 
mice analyzed by quantitative realtime PCR.  12-14 weeks old mice were fed with dox food (1g/kg) for 17days. 
Hp1bp3 mRNA was used as endogenous control. (All data are presented as mean ± SEM; n=3 males; 
wt=wildtype, C57BL/6NTac) 
 
3.2 Phenotypical analysis of inducible Sirt2-knockdown mice 
In the following experiments, the consequences of inducible Sirt2 silencing were 
analysed by employing the standard tet-inducible H1 system as depicted in Figure 6A (lower 
panel). 
 
3.2.1 Knockdown efficiency demonstrated by two individual shRNAs against Sirt2 
Inducible and ubiquitous knockdown of Sirt2 was verified on two transgenic mouse 
lines consisting each of an independent shRNA, shSirt2-2 or shSirt2-6, respectively. 
Consistently, in both mouse lines, Sirt2 mRNA was significantly reduced to 90-95% after a 14 
days induction with dox (1g/kg) (Figure 8A-B). The second transgenic mouse line carrying the 
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shRNA2-6 has mainly been used to confirm Sirt2 knockdown, excluding off-target effects 
(Figure 8B).   
In the absence of dox, shRNA expression is blocked by the tetR, nonetheless, a small 
but significant decrease of Sirt2 mRNA was found in the hypothalami of un-induced mice, 
indicating a low level of spontaneous shRNA expression in this tissue (Figure 8A).  
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Figure 8: Two specific shRNAs against Sirt2 results each to an efficient Sirt2 knockdown in vivo 
A) Relative mRNA levels (wt control = 100%) of tissues from wt control+dox (white bar), shSirt2-2 H1 (grey 
bars) and shSirt2-2 H1+dox (black bars) mice analyzed by quantitative realtime PCR.  Four weeks old control and 
shSirt2-2 transgenic males were fed with dox food (1g/kg) for 14days. Hp1bp3 mRNA was used as endogenous 
control. B) Relative mRNA levels (wt control = 100%, not shown) of tissues from shSirt2-6 H1+dox (grey bars) 
  Results 
 
 60 
in comparison with relative mRNA levels of shSirt2-2 H1+dox animals (black bars) dedicated in A) to confirm 
Sirt2 knockdown.  8-14 weeks old control and shSirt2-6 transgenic females were fed with dox food (1g/kg) for 
14days. Hp1bp3 mRNA was used as endogenous control.  (All data are presented as mean ± SEM; n=3; 
wt=wildtype, C57BL/6NTac). 
 
 
To investigate the impact of ubiquitous shRNA mediated silencing of Sirt2 on diet-
induced obesity, control mice and inducible Sirt2 knockdown mice were fed either a normal 
chow (NCD) or were exposed to a high fat diet (HFD) for 14 weeks. In addition, for induction 
of shRNA mediated transcription, chow diet was supplemented with 1g/kg dox and induction 
was started on mice at an age of 6 weeks for up to 8 weeks. Again, there was a highly and 
efficient decrease of 80-95% in Sirt2 mRNA expression regardless of which diet food mice 
were exposed to (Figure 9A-B). A weak activity of RNAi in animals fed without inductor was 
noticed for the brain lysate which is in accordance with similar results using tet-inducible H1 
configuration (69). To exclude any dox content in the conventional NCD food, a sensitive in 
vitro assay was performed and the presence of dox in mouse-serum was analyzed. These data 
indicate that all mice were fed correctly with or without the inductor (Figure 9E-F). Moreover, 
Sirt2 knockdown could also be confirmed on protein level by an immunoblot only in mice 
transgenic for shSirt2-2 construct and when fed the dox-containing diet (Figure 9C-D). 
In summary, regardless of which diet shSirt2-2 transgenic mice were exposed to, a 
significant and ubiquitous knockdown of Sirt2 has been shown on protein and on mRNA 
expression level. Moreover these findings could be confirmed by a second shRNA (shSirt2-6) 
against Sirt2 in vivo.  
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Figure 9: Sirt2 knockdown in mice exposed to a NCD or HFD  
A) Expression of Sirt2 mRNA in wt control+dox (n=6; white bar), shSirt2-2 H1 (n=6; grey bars) and shSirt2-2 
H1+dox (n=6; black bars) mice as measured by quantitative realtime PCR (wt control = 100%). 14 weeks old 
mice were fed on a NCD supplemented with dox (1g/kg) for 8 weeks. Hp1bp3 mRNA was used as endogenous 
control. B) Expression of Sirt2 mRNA in wt control+dox (n=3; white bar), shSirt2-2 H1 (n=3; grey bars) and 
shSirt2-2 H1+dox (n=3; black bars) mice as measured by quantitative realtime PCR (wt control = 100%). 14 
weeks old mice were fed on a HFD supplemented with dox food (1g/kg) for 8 weeks. Hp1bp3 mRNA was used as 
endogenous control. C, D) Western blot analysis of Sirt2 and Proteinkinase B (Akt) expression (loading control) 
in muscle, liver, brain lysate and epidigonadal white adipose tissue (EWAT) of wt control and shSirt2-2 
transgenic mice fed either on a NCD (n=3 per group; C) or a HFD (n=3 per group; D). E, F) Presence of dox in 
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the serum of un-induced mice transgenic for shSirt2-2 (shSirt2-2-dox) or dox induced mice transgenic for shSirt2-
2 (shSirt2-2+dox) fed on NCD(E; n=6 per group) or fed on HFD (F; n=8 per group) supplemented with dox 
(1g/kg). As control, serum from wildtype animals which were watered with or without dox in drinking water 
(2mg/ml) was used. The test was performed with ES-cells harboring an inducible reporter gene expression 
cassette. Only in the presence of dox, high enzymatic activity of the reporter gene Firefly Luciferase (Fluc), which 
is measured in relative light units (RLU), is shown (black filled symbols). In contrast, serum from un-induced 
animals, have low enzymatic Fluc activity that is comparable to background activity. All data are presented as 
mean ± SEM; control=C57BL/6NTac wildtype mice) 
 
3.2.2 The effect of Sirt2 knockdown on energy homeostasis control 
Under NCD all groups displayed an indistinguishable body weight growth curve (Figure 
10A). Furthermore, although induction with dox was started when mice were 6 weeks, animals 
with a silencing in Sirt2 did not differ significantly from their respective controls illustrated in 
Figure 10A. In line with body weight, no differences could be observed in body fat percentage 
as well (Figure 10B). In the same vein, food intake analysis for one week revealed no 
differences in food intake of shSirt2-2+dox and control+dox mice fed NCD (Figure 10C). 
Calorimetric analysis revealed similar oxygen consumption between Sirt2 knockdown and 
control mice and also fuel preference as determined by respiratory quotient as well as activity 
was comparable between both groups (Figure 10D-F).  
Taken together, induced Sirt2 knockdown mice show no obviously effect in the control of 
energy homeostasis, when fed on a normal chow diet. Thus, efficient postnatal knockdown of 
Sirt2 does not affect overall survival and basic metabolism.  
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Figure 10: Knockdown of Sirt2 does not affect metabolic control on normal diet 
A) Body weight curves of control (triangle, n=7), control+dox (circle, n=7), shSirt2-2 transgene (square, n=6) and 
shSirt2-2 transgene+dox (diamond, n=6) mice on normal diet. Animals were 6 weeks old before inductor was 
initiated throughout the term of the experiment. B) Body fat percentage of control+dox (n=6) and shSirt2-2 
transgene+dox (n=6) animals of 14 weeks old mice fed for 8 weeks on normal diet, supplemented with dox. Data 
results from nuclear magnetic resonance (NMR) analysis. C) Daily food intake of 9 weeks old control+dox (n=7) 
and shSirt2-2 transgene+dox (n=6) animals fed for 3 weeks on normal diet, supplemented with dox. D) Daily and 
nightly oxygen consumption of 13 weeks old control+dox (n=7) and shSirt2-2 transgene+dox (n=6) animals. 
Oxygen consumption was calculated per kg lean mass of each individual mouse. E, F) Determination of 
respiratory quotient (RER) and activity at day and night of control+dox (n=7) and shSirt2-2 transgene+dox (n=6) 
animals fed for 7 weeks on normal diet, supplemented with dox. (All data are presented as mean ± SEM) 
 
 
When fed the same time with HFD, mice gained more body weight with an average 
maximum of approximately 31g after 11 weeks, compared to mice fed on NCD that gained 
about 26g. While body weight was unchanged between shSirt2-2+dox and control+dox mice, a 
decrease was observed surprisingly for control shSirt2-2 transgenic mice fed without an 
inductor (Figure 11A). Body fat content, food intake as well as calorimetric analysis were 
comparable between Sirt2 knockdown and control animals (Figure 11B-F).  
Taken together, a knockdown of Sirt2 resulted in unchanged body weight gain, food 
intake and body fat composition whereas a lower activity was indicated during the night by 
trend when fed on a HFD.  
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Figure 11: Knockdown of Sirt2 does not affect metabolic control on high fat diet 
A) Body weight curves of control (triangle, n=7), control+dox (circle, n=7), shSirt2-2 transgene (square, n=6) and 
shSirt2-2 transgene+dox (diamond, n=6) mice on HFD. Animals were 6 weeks old before inductor was initiated 
throughout the term of the experiment. B) Body fat percentage of control+dox (n=6) and shSirt2-2 transgene+dox 
(n=6) animals of 14 weeks old mice fed for 8 weeks on normal diet, supplemented with dox. Data results from 
nuclear magnetic resonance (NMR) analysis. C) Daily food intake of 9 weeks old control+dox (n=7) and shSirt2-
2 transgene+dox (n=6) animals fed for 3 weeks on normal diet, supplemented with dox. D) Daily and nightly 
oxygen consumption of 13 weeks old control+dox (n=7) and shSirt2-2 transgene+dox (n=6) animals. Oxygen 
consumption was calculated per kg lean mass of each individual mouse. E, F) Determination of respiratory 
quotient (RER) and activity at day and night of control+dox (n=7) and shSirt2-2 transgene+dox (n=6) animals fed 
for 7 weeks on normal diet, supplemented with dox. (All data are presented as mean ± SEM; shSirt2-2 vs control 
*, p ≤ 0.05; **, p ≤ 0.01) 
 
 
3.2.3 Effect of Sirt2 knockdown focused on glucose metabolism  
To further elucidate whether postnatal knockdown of Sirt2 alter glucose metabolism in 
mice, blood glucose levels of random fed mice were analyzed. Six days after dox 
administration, blood glucose was comparable between all groups (Figure 12A). In addition a 
glucose tolerance test (GTT) was performed of 8 weeks old mice fed on NCD and 2 weeks 
feeding with the inductor. Mice were fasted for 16h, followed by an intraperitoneal (i.p.) 
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glucose injection (10 ml of 20% Glucose solution/kg body weight). Subsequently blood 
glucose levels were determined after 15, 30, 60 and 120 min after injection. Due to the high 
level of blood glucose after injection, ß-cell mediated release of insulin is induced, to force 
glucose uptake into tissues like muscle and liver. As depicted in Figure 12B, control and Sirt2-
knockdown mice obtained a similar increase in blood glucose levels after injection and both 
groups returned to a similar value after 120 min. Furthermore, to examine insulin sensitivity, 
an insulin tolerance test (ITT) was performed. Thus, blood glucose concentrations were 
determined 15, 30 and 60 min after an i.p. injection of insulin (0.75 U/kg BW). However, 
Sirt2-knockdown mice displayed no significant change in insulin sensivity compared to their 
control (Figure 12C). 
In summary, there are no alterations in glucose metabolism and insulin sensivity of 
Sirt2 knockdown animals compared to control group when fed on NCD. 
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Figure 12: Unchanged glucose metabolism in Sirt2 knockdown mice on normal diet 
A) Blood glucose of random fed mice was determined of control (white bar; n=7), control+dox (light grey bar; 
n=7), shSirt2-2 (dark grey bar; n=6) and shSirt2-2+dox (black bar; n=6) mice at the age of 6 weeks and after dox 
administration of 6 days on normal diet. B) GTT of control+dox (circle) and shSirt2-2+dox (diamond) mice on 
fasted state at the age of 8 weeks. C) ITT of control+dox (circle) and shSirt2-2+dox (diamond) mice with free 
access to food at the age of 9 weeks. (All data are presented as mean ± SEM) 
 
 
Mice with an induced insulin resistance due to their exposure of HFD were subjected to a 
GTT and ITT. Control+dox and shSirt2-2+dox mice responded similarly to exogenous glucose 
processing as well as to random blood glucose level (Figure 13A, C). Also during an ITT, no 
significant alterations were observed, compared to their control group (Figure 13B). In a 
further approach circulating insulin concentrations were determined from serum of fasted mice 
at two different time points. As shown in Figure 13D serum insulin concentrations of Sirt2 
knockdown animals were comparable to controls at any time point. When measured serum 
leptin concentrations of fasted mice, no significant differences between both groups could be 
demonstrated as well (Figure 13E). 
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Taken together, glucose metabolism was unaffected as well as regulation of energy balance 
of Sirt2 knockdown mice fed on a HFD. 
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Figure 13: Unchanged glucose metabolism and energy balance in Sirt2 knockdown mice on high fat diet 
A) GTT of 8 weeks old control+dox (circle) and shSirt2-2+dox (diamond) mice on fasted state. B) ITT of 
control+dox (circle) and shSirt2-2+dox (diamond) mice with free access to food at the age of 11 weeks. C) Blood 
glucose of random fed mice was determined of control (white bar; n=7), control+dox (light grey bar; n=7), 
shSirt2-2 (dark grey bar; n=6) and shSirt2-2+dox (black bar; n=6) mice at the age of 6 weeks and after dox 
administration of 6 days on high fat diet. D) Circulating serum insulin concentrations of fasted mice at the age of 
8 and 11 weeks. E) Circulating leptin concentrations of fasted mice at the age of 8 and 11 weeks. (All data are 
presented as mean ± SEM; shSirt2-2+dox vs control+dox *, p ≤ 0.05) 
 
Additionally, adipocyte size from control and Sirt2 knockdown mice was monitored on 
either diet. Microscopically analysis revealed no obvious alteration in morphology between 
both groups (Figure 14A-B). Moreover, when quantified adipocyte size, the mean cell size of 
mice on normal chow diet or high fat diet reached approximately 1000 µm and 2000 µm, 
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respectively, with no significant changes between control mice and Sirt2 knockdown mice 
(Figure 14C). 
In a murine adipose 3T3 cell culture system, Wang and his colleagues reported that Sirt2 
knockdown cells had higher expression of markers of adipocyte differentiation, such as PPARγ 
compared to controls (132). To determine these findings in vivo, PPARγ mRNA was measured 
by quantitative realtime PCR in white adipose tissue of wt control mice, shSirt2-2 transgenic 
mice and shSirt2-2+dox transgenic mice (Figure 14D). The data clearly demonstrate 
unchanged level of PPARγ mRNA in Sirt2 knockdown animals on either diet, compared to wt 
controls.   
  Taken together, no alteration was observed in adipocyte morphology and size of Sirt2 
knockdown mice compared to control group when fed on NCD or HFD. Furthermore, a 
knockdown of Sirt2 did not lead to higher expressions of the key adipogenic factor PPARγ in 
vivo. 
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Figure 14: Effect of Sirt2 KD on adipocyte size and PPARγ mRNA expression in EWAT 
A) H&E staining of epigonadal white adipose tissue of 14 weeks old control and Sirt2 knockdown mice on NCD, 
supplemented with dox. Scale bar: 100 µm. B) H&E staining of epigonadal white adipose tissue of 14 weeks old 
control and Sirt2 knockdown mice on HFD, supplemented with dox. Scale bar: 100 µm. C) Quantification of 
mean adipocyte size in epigonadal white adipose tissue of control and Sirt2 knockdown animals on normal chow 
diet and high fat diet at the age of 14 weeks (n=2 per group). D) Expression of PPARγ mRNA in EWAT of wt 
control+dox, shSirt2-2 H1 and shSirt2-2 H1+dox mice as measured by quantitative realtime PCR (wt control = 
100%).  14 weeks old mice were fed on NCD or HFD. Food that is supplemented with dox (1g/kg) is indicated by 
a plus, whereas duration of induction was 8 weeks. Hp1bp3 mRNA was used as endogenous control. 
 
Another objective was to check whether Sirt1 expression is changed in Sirt2 knockdown 
mice, since Sirt1 has been linked to metabolism in mammals. Sirt1 regulates glucose 
metabolism and cholesterol homeostasis by modulating PGC1α/PPARγ and lipid metabolism 
(170). In pancreatic cells, Sirt1 modulates glucose-stimulated insulin secretion in beta cell 
(111, 171). Moreover, in adipose tissue, Sirt1 interacts with PPARγ and aP2 promoters, to 
inhibit adipogenesis (107). To investigate Sirt1 mRNA expression in mice with a Sirt2 
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knockdown, different tissues such as liver, muscle and EWAT were analyzed. As dedicated in 
Figure 15, Sirt1 mRNA expression level is unchanged in Sirt2 knockdown animals compared 
to wt control mice or shSirt2-2 transgenic mice that were not fed with dox containing food. 
Thus, these findings suggest, that Sirt1 has no compensatory function in Sirt2 knockdown 
mice.  
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Figure 15: Sirt1 mRNA expression in Sirt2 knockdown animals fed on HFD 
Expression of Sirt1 mRNA in liver, EWAT and muscle of wt control+dox, shSirt2-2 H1 and shSirt2-2 H1+dox 
mice as measured by quantitative realtime PCR (wt control = 100%).  14 weeks old mice were fed on HFD. Food 
that is supplemented with dox (1g/kg) is indicated by a plus, whereas duration of induction was 8 weeks. Hp1bp3 
mRNA was used as endogenous control. 
 
3.2.4 The effect of Sirt2 knockdown during embryogenesis 
It has not yet been revealed if Sirt2 plays any essential role during development. To study 
any potential effect on Sirt2 knockdown during embryonic development, female wildtype 
controls were given dox-supplemented water for 7 days and then paired with males which were 
transgenic for shSirt2-2. From this time on, the breedings had access to dox in drinking water 
as well until one week after offspring’s birth. In case of lethal embryonic effect, only wildtype 
littermates were expected to survive. Subsequently, one week after birth, all littermates were 
analyzed by PCR genotyping and hepatic Sirt2 knockdown was determined by quantitative 
realtime PCR. As depicted in Figure 16A, PCR revealed shSirt2-2 transgenic mice. 
Interestingly, the ratio of wildtype and transgenic littermate was 72% to 28%. Since 50% 
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wildtypes and 50% transgenic animals are to be expected, these data indicate that there might 
be an effect of embryonic Sirt2 knockdown on embryonic survival (Figure 16B).  Nonetheless, 
using quantitative realtime PCR analysis, a Sirt2 knockdown of 90% on mRNA level was 
established for shSirt2-2 transgenic offspring compared to their wildtype littermates, indicating 
that in surviving transgenic animals, Sirt2 knockdown was successful (Figure 16C).  
In conclusion, Sirt2 gene expression was suppressed during embryonic processes,   
mimicking a conventional knockout. Resulting offspring consist of viable wildtype as well 
transgenic mice with a rate that is shifted to wildtype littermates, indicating a possible role of 
Sirt2 on embryonic survival.   
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Figure 16: Possible role of Sirt2 in regulatory networks controlling embryonic processes 
A) Genotyping PCR of 7 days old littermates with respective controls: H2O control, wildtype control and a 
targeted control. The signal for targeted animals (No3, 4, 5, 8, 19) results in a ~365bp band indicated by a plus, 
whereas no signals are shown for wildtype and H2O control. B) Distribution of wildtype and shSirt2-2 transgenic 
animals. In a total of 25 offspring, 18 mice were wildtype and 7 mice comprise the targeted allele. C) Quantitative 
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realtime PCR analysis of Sirt2mRNA from liver of 7 days old wildtype mice (grey bar; n=4) and shSirt2-2 
transgenic mice (black bar; n=4).  (All data are presented as mean ± SEM; shSirt2-2+dox vs control+dox ***, p ≤ 
0.001) 
 
3.2.5 The effect of Sirt2 knockdown in neurodegenerative disease 
Parkinson Disease (PD) is characterized by the development of α-synuclein containing 
inclusions (termed Lewy bodies) and a loss of dopaminergic neurons in the substantia nigra 
(172), which is accompanied by muscle rigidity, bradykinesia, resting tremor and postural 
instability, eventually leading to death.  Dopaminergic neurons are necessary for tasks specific 
to the brain regions that they innervate, including motor behavior, motivation and working 
memory (173) and reside mainly in the zona compacta of the substantia nicgra (SNc) and 
ventral tegmental area (VTA) (174). A recent study demonstrated that Sirt2 inhibition by 
siRNAs prevented α-synuclein cytotoxicity and modified inclusion morphology in cellular 
models of PD. In addition, Sirt2 inhibitors were found to ameliorate dopaminergic cell death in 
vitro and in a Drosophila model of Parkinson’s disease (141). 
To study the role for SIRT2 in the control of neuronal metabolism in a mouse model of 
PD in vivo, Sirt2 transgenic and control mice were treated either with 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that causes permanent symptoms of 
Parkinson's disease by destroying dopaminergic neurons in the substantia nigra of the brain, or 
alternatively with saline. MPTP (20 mg/kg) was administrated i.p. four times in one day at 2 
hours intervals. Mice used as controls received an equivalent volume of saline (0.9%). To 
study motor disability, a Rotarod test was performed on control and shSirt2-2 transgenic mice 
one week before and one week upon treatment with MPTP or saline, respectively (Figure 17A-
B). In this experiment mice are placed on an accelerating rotating rod, whereas the length of 
time that animals stay on the rod was monitored. The data shown in Figure 17B derived from 
the Rotarod performance one week after MPTP or saline treatment, while the first run on the 
Rotarod served for training and adaptation to the system. The control (wt) mice treated with 
MPTP seemed to stay shorter on the rod, indicating locomotor impairment, compared to 
control animals treated with saline. Data from Rotarod performances of Sirt2 knockdown mice 
treated with MPTP suggest a possible rescue effect for these mice since the time on the rod was 
similar to Sirt2 knockdown mice treated with saline. However, although not significantly, dox 
induced transgenic animals treated with saline seemed to stay generally shorter on the rod, 
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compared to wt controls treated with saline, which can likely to be misleaded (Figure 17B). 
Thus, from these results it is not yet clear, if Sirt2 knockdown mice injected with MPTP have a 
rescue effect, although they do not differ much from Sirt2 knockdown animals treated with 
saline, concerning the time on the rod. However, Rotarod performances done one week before 
application of MPTP or saline indicate no differences in behaviour and any impairment of Sirt2 
knockdown mice at the beginning of the experiment (Figure 17A).  
In addition, the knockdown of Sirt2 mRNA was measured in vivo by quantitative 
realtime PCR, from different sections of the brain tissue, such as ventral tegmental area (VTA), 
hypothalamus (Ht), caudate putamen (Cpu), nucleus accumbens (NaC) and frontal association 
cortex (Fra). A strong decrease in Sirt2 mRNA could be observed for induced mice transgenic 
for shSirt2-2, demonstrated for MPTP or saline treated animals (Figure 17C-D). 
 Taken together, with these experiments it was not possible to clarify if a Sirt2 
knockdown in mouse models of PD prevents from neuronal cell death.   
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Figure 17: Rotarod analysis and knockdown efficiency of Sirt2 knockdown and wt control mice treated 
either with MPTP or saline   
A) Rotarod analysis of Sirt2 knockdown and control mice. Total time of Sirt2 knockdown (striped bar; n=10) and 
control mice (black bar; n=9) staying on the rod until mice fell from the Rotarod was measured. B) Rotarod 
analysis of 22 weeks old Sirt2 knockdown and control mice one week after treatment with MPTP or saline. 
(wt+dox NaCl, n=5; wt+dox MPTP, n=3; shSirt2-2+dox NaCl, n=4; shSirt2-2+dox MPTP, n=3). C, D) 
Expression of Sirt2 mRNA was measured one week after treatment with saline (C) or MPTP (D) in different 
sections of brain tissue by quantitative realtime PCR. 22 weeks old shSirt2-2 transgenic mice and control mice 
were fed with NCD supplemented with dox (1g/kg) for 14 weeks (n=3 per group). VTA=ventral tegmental area; 
Ht=hypothalamus; CPU=caudate-putamen; NAc=nucleus accumbens; Fra=frontal association cortex
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4 Discussion 
During the course of this work a new system was developed to allow spatial and 
temporal control of gene expression by RNA interference. Therefore a dox inducible shRNA 
expression system was combined with a conditional Cre/loxP configuration. Analysis in mouse 
ES cells displayed equal levels of gene silencing compared with the standard inducible H1-tet 
promoter. Surprisingly, analysis of mice carrying the temporal and spatial controllable system 
showed a lower degree of gene silencing than mice carrying the standard inducible H1-tet 
promoter. Thus, this system is only suited to a limited extent for analysis of gene function in 
vivo. 
 
4.1 Spatially and temporally controlled RNAi  
Recently a H1 promoter based inducible tet-repressor system (H1-tet) has been described 
for ubiquitously gene silencing (69). Therefore this system was used for temporal control and 
combined with the Cre loxP technology to achieve spatial regulation. Various H1 promoter 
configurations were developed in which the promoter activity is interrupted by a loxP sites 
flanked stuffer sequence, called promoter inhibitory element (PIE). Recombination between 
the two loxP sequences through a Cre recombinase results in a deletion of PIE and a restore of 
the promoter activity followed by shRNA mediated gene silencing. However, the success of 
this approach is contingent on: i) that the promoter inhibitory element disrupts promoter action; 
and ii) that the presence of the remaining loxP site does not compromise promoter activity.  
As the latter requirement seems to be the pivotal factor in this system, a screen was 
performed in mouse ES cells after the Cre recombination mediated event. Experiments 
revealed a deficit in promoter activity for all conformations with a modification within the H1 
promoter, demonstrated by strongly reduced shRNA expression levels (Figure 5). Since the H1 
promoter exhibits an extremely compact structure, this decline in promoter activity is possibly 
due to the residual loxP site. Myslinski and colleagues have demonstrated that sequence 
substitution in the region between the PSE and the TATA motif of the H1 promoter resulted in 
a significant reduction in RNA synthesis, both in vitro and in vivo (175). These findings are in 
line with our results (constructs 1, 2 and 4; Figure 4), indicating critical spacing within this 
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region. Although the distance between DSE and PSE was unaltered in construct 3, shRNA 
expression was reduced, arguing for conserved sequences between these elements. In the same 
line, other positions between DSE/PSE and between DSE submotifs led to an inactivation of 
the promoter, indicated in the results of construct 6 and 7 (Figure 5).  
Altogether, each approach that included a modification of the H1 promoter resulted in 
promoter repression and in strongly reduced shRNA expression. Based on this data, the H1 
promoter is not compatible with integration of a single loxP site.  
As an alternative strategy, elements from the U6 promoter (DSE and 150bp spacing 
region) and the H1-tet promoter (PSE, TATA motif) were combined in which promoter 
sequences of the U6 spacing region were replaced by a single loxP site. Despite of the 
remaining loxP site, only this approach reached a shLacZ expression level comparable to the 
unaltered H1-tet system, as depicted in Figure 5. In contrast, shLacZ expression was not found 
in the presence of PIE, implementing successful interruption of the promoter activity of 
construct 5 (Figure 5). These findings are in line with the results of McMahon et al., who 
studied three regions between the PSE and DSE in the U6 promoter for optimal loxP 
placements by replacing promoter sequences, and no disturbance of the U6 promoter activity 
was found in vitro and in vivo (68).  Taken together, these findings show that the U6 promoter 
is more compatible and suited for modifications. In combination with promoter elements of 
H1, a system was developed that fulfilled the criteria for promoter repression by PIE and 
allowed for reactivation of promoter activity after Cre mediated recombination in mouse ES 
cells. 
To corroborate these results in vivo, mice were generated carrying the U6/H1-tet 
promoter system that is conjugated with a tet-repressor expression cassette, allowing for 
inducible RNAi. The U6/H1-tet configuration was explored in two mouse lines using shRNAs 
against the target genes LacZ or Sirt2, respectively. To study knockdown levels in all tissues 
after PIE deletion, these mice were further crossed with a Cre-deleter strain. Gene silencing 
progressed after addition of the inducer doxycycline.   
Surprisingly, the knockdown level in vivo using the U6/H1-tet system were about 3-6 
fold weaker, analyzed for both, shLacZ and shSirt2-2 carrying transgenic animals, compared to 
the  knockdown level resulted by the commonly used inducible H1-tet promoter system. Note 
that the standard H1-tet promoter contains no loxP site. Incomplete recombination could result 
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in inefficient promoter activation followed by decreased gene silencing. The promoter 
inhibitory element represents the fluorescence marker gene Zsgreen that is under control of the 
ubiquitin promoter. To rule out incomplete recombination, mRNA levels of Zsgreen were 
determined of mice before and after Cre recombination. No Zsgreen mRNA was detected after 
Cre recombination, confirming a complete removal of PIE (Figure 6).  
In conclusion, the U6/H1-tet system yields acceptable knockdown levels for Sirt2 
indicating that this approach can be applied for highly efficient shRNAs. On the other hand, 
high and efficient gene silencing is restricted to a selection of tissues, limiting this system to 
use in these. 
 
4.2. Phenotypical analysis of Sirt2 knockdown in mice 
The founding member of the sirtuins, the Sir2 protein (silent information regulator 2) 
from the budding yeast Saccharomyces cerevisiae,  is an NAD-dependent deacetylase that 
connects metabolism with longevity in yeast, worms and flies (80-82, 176). In mammals, Sir2 
is represented by seven homologues, termed Sirt1 through Sirt7 (177). In addition of histones, 
also non-histone proteins  are found to be deacetylated by sirtuins (98, 178, 179). Sirt1 is the 
most studied member of the sirtuin family that has been linked with metabolic control, 
modulating downstream biological processes by deacetylating specific transcription factors, 
co-repressors, and co-activators, including p53, PGC-α, NF-kB, MyoD, PPARγ and members 
of the FoxO familiy (105, 107, 115, 117, 180).  The three sirtuins, Sirt3, Sirt4, and 5 are 
predominantly localized in the mitochondria (79, 99, 100). There is growing evidence linking 
mitochondrial sirtuins with regulating energy usage and human lifespan (148, 181), since 
mitochondrial dysfunction is also associated with mammalian aging and diseases, including 
diabetes, neurodegenerative diseases, and cancer (182). The functions of Sirt 4-7 are less 
known.  It has been shown that Sirt6 may also be involved in aging in mice, while Sirt7 appear 
to regulate DNA pol I transcription (154, 156, 183). 
In contrast to other sirtuins, Sirt2 protein is mainly distributed throughout the 
cytoplasm while only a minor fraction is located in the nucleus (102, 126, 184). Sirt2 is able to 
deacetylate α-tubulin that is required for normal mitotic repression (101, 124) and that controls 
mitotic checkpoint functions in early metaphase to prevent chromosomal instability (123, 127). 
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A metabolic regulation function of Sirt2 was postulated since inhibition of Sirt2 resulted in 
suppression of adipocyte differentiation (131, 132). A previous study reported an up-regulation 
of Sirt2 expression in adipose tissue by fasting (130, 132). Elevated Sirt2 expression was 
observed in kidney and adipose tissue when mice were dietary restricted for 18 month (130) 
but also by shorter-term nutrient deprivation in the form of 24 h fasting (132). Sirt2 was also 
described as an oligodendroglial cytoplasmic protein, localized to the outer and juxtanodal 
loops of the myelin sheath (134, 135). In the central nervous system the deacetylation activity 
of Sirt2 may appear detrimental to neuronal health. For example, SIRT2 may oppose resistance 
to axonal degeneration and inhibition of SIRT2 rescued α-synuclein toxicity and protected 
against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson’s disease 
(136, 141).  
Since most functional roles for Sirt2 were studied in cellular systems, these purported 
roles of Sirt2 remain to be confirmed in vivo. In this work the effect of Sirt2 knockdown in 
mice was studied with the focus on glucose and energy homeostasis, developmental regulation 
and neurodegenerative disease.  
 
4.2.2 The role of Sirt2 knockdown during embryogenesis 
To elucidate the role of Sirt2 in regulatory networks controlling embryonic processes, 
Sirt2 was downregulated during gametogenesis and embryogenesis thereby mimicking a 
constitutive Sirt2 knockout. For this purpose a knockdown of shSirt2-2 transgenic males was 
initiated at mating start with wildtype females by the inducer doxycycline that was 
supplemented into the drinking water.  A Sirt2 knockdown in early processes of embryogenesis 
is feasible, since it was demonstrated in rodents that dox passes the placenta of pregnant 
females and is also excreted into breast milk (185, 186). Data from genotyping showed that 
also animals carrying the shSirt2-2 allele were present among the viable offspring, but their 
proportion was about half what was expected. In addition, when measuring Sirt2 mRNA levels 
in the liver of these transgenic littermates, a strong reduction could be confirmed. However, 
lower levels of Sirt2 protein do not seem to induce embryonic lethality. Although offspring 
from most of the other sirtuin knockouts are viable, Sirt1 knockout mice experienced 
embryonic lethal in inbred strain backgrounds (e.g. Reference (187), or if survived in an 
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outbred background strain, they died in the perinatal period, exhibiting growth retardation and 
developmental defects in various tissues including eye, lung, pancreas, heart, and reproductive 
system (188, 189). In addition, Sirt6 knockout mice are born normally, but display early 
postnatal onset of growth retardation and failure to thrive, with a maximal lifespan of 24 days 
(154). In an expression profile of Sirt genes in human organs, expression levels of Sirt2 were 
higher in adult brain compared to fetal brain, possibly indicating a less important role in 
developmental processes (145). Moreover, in an unpublished observations reported in Vaquero 
et al., Sirt2 knockout mice were described inconspicuously (125). On the other hand it was 
demonstrated that Sirt2 interacts with HOXA10, an evolutionarily conserved homeobox 
transcription factor important for cell-type determination during embryogenesis (190).  
In conclusion, a Sirt2 knockdown during embryogenesis apparently has no impact in 
developmental processes. However, it remains to be determined whether Sirt2 knockdown 
animals show developmental defects in the perinatal period and if further studies confirm a 
proportion more shifted to wildtype littermates than transgenic animals as it was observed in 
this work. 
   
4.2.2 The effect of Sirt2 knockdown on glucose and energy homeostasis 
A growing interest of the sirtuin research involves the regulation of metabolism. 
Maintenance of energy homeostasis requires a coordinated regulation of energy intake, storage, 
and expenditure. Abnormal metabolic homeostasis can have severe consequences and often 
manifests as syndromes such as obesity and type II diabetes mellitus. Moreover, signs of 
metabolic imbalance, such as insulin resistance, are observed with increasing frequency during 
aging. The identification of central pathways that regulate metabolic homeostasis is an area of 
intense sirtuin research and has important implications for understanding molecular networks 
and for treating metabolic diseases. 
In the present work, metabolic characteristics of dox induced Sirt2 knockdown mice 
were examined fed either a normal diet or a high fat diet and compared to their respective 
controls (wildtype animals fed with the inductor dox, wildtype animals and shSirt2-2 
transgenic animals fed without inductor). The course of body weight gain of Sirt2 knockdown 
animals increased similarly to those of controls when started with dox induction. Also body fat 
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content of Sirt2 knockdown animals was comparable to their controls. These results were in 
line with data from food intake and indirect calorimetric measurements displaying no 
significant alteration, indicating no distinct effects in energy absorption as well as expenditure, 
regardless whether mice were fed on a normal or a high fat diet. Nonetheless, the knockdown 
of Sirt2, evaluated for various tissues was high and reached levels of about 80-90%. Western 
Blot analysis confirmed the strong reduction of Sirt2 protein. 
Adipose tissue is a critical regulator of metabolism, being the major storage for lipids, 
while also regulating systemic metabolism through the release of lipids and hormones such as 
leptin (191, 192). Without a change in energy balance an increase in adipogenesis would result 
in smaller fat cells with no change in total adiposity and a reduction in adipocyte number 
would result in larger fat cells, but not less total adipose mass (193). In the study of Jing et al., 
it was demonstrated on an murine adipose 3T3 cell culture system that a knockdown of Sirt2 
promotes adipogenesis, whereas overexpression leads to an opposite effect (131). Hence, white 
adipose tissue was investigated microscopically for changes in morphology and notably, the 
adipocyte size was indistinguishable between Sirt2 knockdown mice and controls, indicating 
that 90% knockdown of Sirt2 does not affect adipogenesis.  
Another sirtuin, Sirt1, also plays a role in fat metabolism. Activation of Sirt1 in mice 
through fasting or  resveratrol treatment, results in a reduction of white adipose tissue, a 
decrease in fat storage and smaller adipocytes (107, 194) whereas inhibition of Sirt1 
significantly increases fat mass (195). The idea emerged that Sirt1 activity may influence the 
effect of Sirt2 knockdown in adipocyte differentiation.  
However, Jing et al. reported elevated acetylation levels of FoxO1 in 3T3-L1 
adipocytes with a Sirt2 knockdown. This effect was specifically attributed to the knockdown of 
Sirt2 and independent from changes in Sirt1 or FoxO1 expression. He further demonstrated  in 
co-immunoprecipitation experiments  a direct interaction of Sirt2 with FoxO1 (131), notably 
Sirt1 was also shown to be able to deacetylate FoxO1 (116, 180, 196). Moreover, Sirt2 
expression was found to be more abundant in white adipose tissue than Sirt1, thus Sirt2 is more 
likely to play a major role in this regard (131). To rule out any influence of Sirt1 in adipocyte 
differentiation in this work, Sirt1 mRNA levels were measured in liver, white adipose tissue 
and muscle of Sirt2 knockdown mice.  The data indicated no altered expression level of Sirt1 
in Sirt2 knockdown mice compared to wildtype controls, irrespective of diet. 
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Increased acetylation of FoxO1 through a Sirt2 knockdown in adipocytes was 
associated with a decrease of FoxO1´s repressive interaction with PPARγ (131, 132). 
Furthermore, mRNA level of PPARγ, a transcription factor central to adipogenic 
differentiation was found to be  increased in Sirt2 knockdown cells (131). Nonetheless, no 
differential expression in PPARγ mRNA level was observed by Sirt2 knockdown in vivo.  
It was noted that Sirt2 knockdown has no apparent influence on the regulation of blood 
glucose, serum leptin and insulin concentrations.  
Taken together, Sirt2 knockdown does not affect glucose or lipid metabolism in vivo. 
Effects reported in a cellular model of 3T3-L1 adipocytes with Sirt2 knockdown, could not be 
confirmed in vivo as well as regulatory modifications of Sirt2 downstream targets. Although 
knockdown efficiency yielded ~90%, it appears possible that the knockdown of Sirt2 was not 
sufficient to alter cellular function, i.e. the residual 10% of Sirt2 protein are able to adequate 
for its cellular functions. It appears likely that the loss of a single sirtuin might be compensated 
for redundant functions conferred by remaining sirtuin family members, although an increase 
of Sirt1 mRNA expression was not observed in this work. Furthermore, functional redundancy 
between sirtuins may account for the failure to confirm the physiological importance of sirtuin 
mediated deacetylation events. Another possibility, although less likely, is that Sirt2 was not 
activated under the conditions studied, suggesting a lesser role in normal physiology for Sirt2. 
 
4.2.3 Effect of Sirt2 knockdown in a mouse model of Parkinson Disease  
Parkinson's disease (PD) is one of the most common progressive neurodegenerative 
disorders, affecting about 2% of people over 65 years old and 4–5% of people over 85. PD is 
characterized by a loss of dopaminergic neurons in the substantia nigra, which is accompanied 
by muscle rigidity, bradykinesia, resting tremor and postural instability (106). By now, the role 
of sirtuins in neuroprotection is not entirely clear. Sirt2 expression was found strongest among 
all sirtuins in brain (128, 133). In neurons, Sirt2 is rather uniformely expressed in all neurites 
and their growth cones (128). Unlike SIRT2, SIRT1 is localized exclusively in neurons (93, 
197-200). Moreover, Sirt2 was established as an inhibitor of oligodendroglial 
differentiation/aging through deacetylation of the microtubule cytoskeleton and in some 
instances the effect of Sirt2 appears to be detrimental to neuronal health. Pharmacological and 
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genetic inhibition of Sirt2 has been shown to protect against  α-synuclein toxicity in cultured 
neurons and in Drosophila suggesting that Sirt2 is involved in promoting neurodegeneration 
(141). 
In this work, the effect of Sirt2 knockdown was analyzed during a progressive loss of 
dopaminergic neurons, induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) that provides one of the most valuable approaches to analyze 
critical aspects of PD in the animal model. Dopaminergic neurons are presented within in the 
vertebrate central nervous system (CNS) with the largest assembly in the midbrain. There, 
dopamine containing neurons are separated into functionally distinct subgroups called the 
substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) based on their 
position within the midbrain (201). These dopaminergic circuits are involved in the control of 
voluntary movement and in emotion based behavior (173). The Rotarod is a widely used motor 
performance test to evaluate MPTP models (202-206). There are three MPTP protocols widely 
used. The acute protocol generally involves 4 injections in one day at 2 h intervals. Depending 
on the doses given, striatal dopamine depletion can range from 40% (14 mg/kg x 4) to 
approximately 90% (20 mg/kg x 4) (207).  Subacute administration is a once daily injection 
(30 mg/kg) for five consecutive days. This regime causes apoptosis and depletes striatal 
dopamine by 40-50 % (207, 208). The chronic regime (25 mg/kg MPTP plus probenecid) is 
over 5 weeks at 3.5-day intervals and striatal dopamine levels are reduced by 90−93% within a 
week, and by 70−80% of the total at 3 to 24 weeks after MPTP/probenecid treatment days 
(209, 210).   
However, in this work, using the acute protocol with four doses MPTP (20 mg/kg) in 
one day, a rescue effect from neuronal cell death through a knockdown of Sirt2 could not be 
derived from Rotarod data. Although the duration time on the rod was similar between Sirt2 
knockdown mice after MPTP or saline treatment, the time on the rod differs between Sirt2 
knockdown animals and wildtype control mice, handled with the placebo. Moreover, this effect 
was not observed on the Rotarod performance one week before injection. It is possible that the 
time necessary to kill dopaminergic neurons may not have been reached in acutely MPTP 
treated mice. This hypothesis may be unlikely given that MPTP-induced neuronal loss reaches 
a maximum 3 days after MPTP intoxication and is nil 7 days after intoxication (211-213). 
Another aspect might be compensatory mechanisms developing in the nigrostriatal pathway. 
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This concept can be supported by the increased ratio of dopamine metabolites to dopamine, an 
index of dopamine turnover seen in the stritatum of acute MPTP treated mice, and the absence 
of motor deficit, reported by Rousselet and colleagues (214). In addition, there are other tests 
such as grid or pole, using skilled forepaw, or measures of sensorimotor function (forepaw 
placement) that are postulated to provide the most sensitive detection of dopamine loss for 
MPTP models, even close to the time of lesion and month later (215). 
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5 Summary 
Within the past eight years, RNA interference (RNAi) has emerged as a powerful 
experimental tool for gene function analysis in mice. Reversible control of shRNA mediated 
RNAi has been achieved by using a tetracycline (tet)-inducible promoter. In the presence of the 
inductor doxycycline (dox), shRNA mediated gene silencing is initiated, whereas RNAi 
mechanism is blocked in the absence of dox. To achieve spatially and temporally regulated 
RNAi, the tet inducible system was combined with a Cre/loxP based strategy for tissue specific 
activation of shRNA constructs. To this end, a loxP-flanked “promoter inhibitory element” 
(PIE) was placed between the proximal (PSE) and distal sequence element (DSE) of a dox 
inducible promoter such that promoter function is completely blocked. Re-activation can be 
achieved through Cre mediated excision of PIE. To allow for gene silencing in a selected 
tissue, Cre expression can be regulated by a tissue-specific promoter. In mouse ES cells, the 
system mediated tight regulation of shRNA expression upon Cre mediated activation and dox 
administration, reaching knockdown efficiencies of >80%. Unexpectedly, the system showed a 
limited activity in transgenic mice when applied for conditional silencing of two different 
targets, LacZ and Sirt2. Sirt2 is a member of the sirtuin family which has considerably gained 
attention in vitro for its possible role in many physiological processes, including adipogenesis 
and neurodegenerative diseases. 
To investigate the function of Sirt2 in vivo, the unmodified dox-responsive and tet-
inducible promoter was further used for conditional RNAi in transgenic mice. Inducible 
shRNA expression resulted in efficient silencing of Sirt2 (>90%) in all tissues which have been 
analyzed. Suppression of Sirt2 during embryogenesis resulted in offspring consisting of equal 
ratios of wild type and transgenic pups, indicating that Sirt2 is not indispensable for 
development. In adult animals, glucose metabolism, insulin sensitivity and energy balance 
appeared to be unaffected by Sirt2 deficiency. Likewise, expression of PPARγ, a downstream 
target of Sirt2, was not found to be altered upon Sirt2 inhibition. Finally, Sirt2 silencing was 
induced in an experimental model of Parkinson disease (PD). Data from Rotarod performances 
to study motor behaviour did not provide any evidence for a role of Sirt2 in PD pathogenesis as 
suggested by previous in vitro studies. Taken together, conditional Sirt2 silencing in vivo does 
not support speculation concerning a central role of Sirt2 in physiological processes, 
embryogenesis and in a mouse model of Parkinson disease. 
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6 Zusammenfassung 
In den letzten acht Jahren hat sich die RNA Interferenz (RNAi) zu einer äußerst 
effizienten Methode entwickelt, um Funktionen von Genen in Mäusen zu untersuchen. Eine 
Regulierung der shRNA Transkription und des RNAi-Mechanismus wurde durch die 
Entwicklung von tet-induzierbaren Promotoren erreicht. In Gegenwart des Induktors 
Doxyzyklin (dox) findet aktiv shRNA Transkription statt, welche RNAi auslöst und zu einer 
Verringerung der Genexpression führt. In Abwesenheit von dox ist der RNAi-Mechanismus 
blockiert. Um RNAi gewebespezifisch und zeitlich regulieren zu können, wurde das tet-
induzierbare System mit der Cre/loxP Technologie kombiniert. Dazu wurde ein loxP-
flankiertes „Promotor inhibitorisches Element“ (PIE) zwischen das proximale (PSE) und 
distale (DSE) Sequenzelement des dox-induzierbaren Promotors platziert, wodurch dessen 
Aktivität vollständig blockiert wurde. PIE kann durch Cre-Rekombination entfernt werden, 
sodass die Promotorfunktion wiederhergestellt wird. Es besteht die Möglichkeit, Cre durch 
einen gewebespezifischen Promotor zu regulieren, womit der „Knockdown“ gezielt in einem 
spezifischen Gewebe stattfindet. In embryonalen Mausstammzellen konnte mit diesem System 
die shRNA Expression nach Aktivierung durch Cre und Induktion mit dox reguliert werden. 
Die Genepression konnte dabei bis zu mehr als 80% herunterreguliert werden. In transgenen 
Mäusen war der „Knockdown“ von zwei verschiedenen Zielgenen, LacZ und Sirt2, unerwartet 
gering. Sirt2 wurde äußerst interessant, nachdem es mit grundlegenden physiologischen 
Prozessen wie Lipogenese und neurodegenerativen Erkrankungen in vitro in Verbindung 
gebracht wurde. 
Um die Rolle von Sirt2 in vivo zu untersuchen, wurde das nicht-gewebespezifische und 
durch dox induzierbare tet-Promotor-System für induzierbare RNAi in Mäusen genutzt. Dabei 
führte die shRNA Transkription in allen untersuchten Geweben zu einer effizienten 
Herunterregulierung der Sirt2-Expression (>90%). Ein „Knockdown“ von Sirt2 während der 
Embryogenese hatte keine Auswirkung auf den Anteil der Wildtyp- und transgenen 
Nachkommen, was vermuten lässt, dass sich ein Verlust von Sirt2 während der Embryogenese 
nicht lethal auswirkt. In ausgewachsenen Tieren schienen Glukosemetabolismus, 
Insulinsensitivität und Energiebilanz nicht durch ein Sirt2 Defizit beeinflusst zu werden. Die 
Expression von PPARγ, einem „Downstream“-Target von Sirt2 war ebenfalls nicht durch 
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einen Sirt2-„Knockdown“ verändert. Abschließend wurde die Funktion von Sirt2 in einem 
Parkinson-Krankheitsmodell untersucht. Ergebnisse aus Rotarod-Studien, die dazu dienen 
motorische Fähigkeiten zu analysieren, ließen keinen Aufschluß über eine Rolle von Sirt2 in 
der Krankheitsentstehung von Parkinson zu. Insgesamt unterstützt ein Sirt2-„Knockdown“ in 
vivo keine Spekulationen bezüglich einer zentralen Rolle von Sirt2 bei physiologischen 
Prozessen, in der Embryogenes und in einem Mausmodell der Parkinson-Krankheit. 
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